appb_10q.htm

0001477932-19-000451.txt : 20190213 0001477932-19-000451.hdr.sgml : 20190213 20190213160153 ACCESSION NUMBER: 0001477932-19-000451 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 38 CONFORMED PERIOD OF REPORT: 20181231 FILED AS OF DATE: 20190213 DATE AS OF CHANGE: 20190213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Applied BioSciences Corp. CENTRAL INDEX KEY: 0001607549 STANDARD INDUSTRIAL CLASSIFICATION: GRAIN MILL PRODUCTS [2040] IRS NUMBER: 811699502 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55523 FILM NUMBER: 19596994 BUSINESS ADDRESS: STREET 1: 9701 WILSHIRE BLVD. STREET 2: SUITE 1000 CITY: BEVERLY HILLS STATE: CA ZIP: 90212 BUSINESS PHONE: (310) 356-7374 MAIL ADDRESS: STREET 1: 9701 WILSHIRE BLVD. STREET 2: SUITE 1000 CITY: BEVERLY HILLS STATE: CA ZIP: 90212 FORMER COMPANY: FORMER CONFORMED NAME: Stony Hill Corp. DATE OF NAME CHANGE: 20161109 FORMER COMPANY: FORMER CONFORMED NAME: First Fixtures, Inc. DATE OF NAME CHANGE: 20140507 10-Q 1 appb_10q.htm FORM 10-Q appb_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2018

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to ____

Commission File No. 000-55523

APPLIED BIOSCIENCES CORP.

(Exact name of registrant as specified in its charter)

Nevada		None
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

9701 Wilshire Blvd., Suite 1000

Beverly Hills, California 90212

(Address of principal executive offices) (Zip Code)

(310) 356-7374

(Registrant’s telephone number, including area code)

____________________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ¨ No x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (check one):

Large accelerated filer	o	Accelerated filer	o
Non-accelerated filer	x	Smaller reporting company	x
		Emerging growth company	x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act): Yes ¨ No x

APPLICABLE ONLY TO CORPORATE ISSUERS

As of February 8, 2019 there were 13,342,113 shares of common stock, $0.00001 par value per share, outstanding.

APPLIED BIOSCIENCES CORP.

QUARTERLY REPORT ON FORM 10-Q

FOR THE PERIOD ENDED DECEMBER 31, 2018

INDEX

Index		Page

Part I. Financial Information

Item 1.	Unaudited Condensed Consolidated Financial Statements	4

	Condensed Consolidated Balance Sheets as of December 31, 2018 (Unaudited) and March 31, 2018.	4

	Condensed Unaudited Consolidated Statements of Operations for the three and nine months ended December 31, 2018 and December 31, 2017.	5

	Condensed Unaudited Consolidated Statements of Stockholders’ Equity for the nine months ended December 31, 2018.	6

	Condensed Unaudited Consolidated Statement of Cash Flows for the nine months ended December 31, 2018 and December 31, 2017.	8

	Notes to Condensed Consolidated Financial Statements (Unaudited).	9

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	15

Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	19

Item 4.	Controls and Procedures.	19

Part II. Other Information

Item 1.	Legal Proceedings.	20

Item 1A.	Risk Factors.	20

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	20

Item 3.	Defaults Upon Senior Securities.	20

Item 4.	Mine Safety Disclosures.	20

Item 5.	Other Information.	20

Item 6.	Exhibits.	21

Signatures		23

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q of Applied Biosciences Corp., a Nevada corporation (the “Company”), contains “forward-looking statements,” as defined in the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “could”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. The economic environment within which we operate could materially affect our actual results. Additional factors that could materially affect these forward-looking statements and/or predictions include, among other things: the possibility that we will not receive sufficient customers to grow our business, the Company’s need for and ability to obtain additional financing, other factors over which we have little or no control; and other factors discussed in the Company’s filings with the Securities and Exchange Commission (“SEC”).

Our management has included projections and estimates in this Form 10-Q, which are based primarily on management’s experience in the industry, assessments of our results of operations, discussions and negotiations with third parties and a review of information filed by our competitors with the SEC or otherwise publicly available. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

3

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1. Financial statements.

APPLIED BIOSCIENCES CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

	December 31, 2018			March 31, 2018
ASSETS	(unaudited)
Current Assets
Cash	$	241,571		$	60,934
Accounts receivable, net of allowance of nil and $887 at December 31, 2018 (unaudited) and March 31, 2018, respectively		17,822			12,386
Inventory		70,105			29,074
Prepaids and other current assets		46,756			124,455
Total Current Assets		376,254			226,849

Property and equipment, net		3,563			4,441
Equity investments		873,300			468,537
Deposit on the acquisition of Trace Analytics, Inc.		550,000			-
Other asset		5,500			5,500

TOTAL ASSETS	$	1,808,617		$	705,327

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities
Accounts payable	$	33,131		$	21,846
Accrued expenses		150,246			14,039
Total Current Liabilities		183,377			35,885
Stockholders' Equity
Preferred stock; $0.00001 par value; 5,000,000 shares authorized; none issued and outstanding at December 31, 2018 (unaudited) and March 31, 2018		-			-
Common stock; $0.00001 par value; 200,000,000 shares authorized; 11,597,110 and 10,499,610 issued and outstanding at December 31, 2018 (unaudited) and March 31, 2018, respectively		116			105
Additional paid in capital		4,960,791			3,054,297
Common stock to be issued, 1,656,500 and 263,000 shares at December 31, 2018 (unaudited) and March 31, 2018, respectively		1,982,352			526,000
Accumulated deficit		(5,299,634	)		(2,901,933	)
Total Applied BioSciences Corp. Stockholders' Equity		1,643,625			678,469
Non-controlling deficit		(18,385	)		(9,027	)
Total Stockholders' Equity		1,625,240			669,442
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	1,808,617		$	705,327

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

Table of Contents

APPLIED BIOSCIENCES CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months			Three Months			Nine Months			Nine Months
	Ended			Ended			Ended			Ended
	December 31, 2018			December 31, 2017			December 31, 2018			December 31, 2017
	(unaudited)			(unaudited)			(unaudited)			(unaudited)

PRODUCT REVENUE, NET	$	413,109		$	62,977		$	472,509		$	179,534

COST OF REVENUE, PRODUCT		379,582			50,370			439,740			140,706

GROSS MARGIN		33,527			12,607			32,769			38,828

EXPENSES
Sales and marketing (including stock based compensation of nil, $47,111, $210,000 and $47,111, respectively)		100,730			165,315			556,167			229,674
General and administrative (including stock based compensation of $1,133,534, $13,889, $1,271,959 and $26,389, respectively)		1,317,469			133,977			1,712,667			358,193
Depreciation and Amortization		292			56,172			877			168,428
TOTAL OPERATING EXPENSES		1,418,491			355,464			2,269,711			756,295
OPERATING LOSS		(1,384,964	)		(342,857	)		(2,236,942	)		(717,467	)
Other Income (Expense)
Unrecognized gain on equity investments		-			-			404,763			-
Interest Expense		(506,579	)		-			(574,880	)		-
Total other income, net		(506,579	)		-			(170,117	)		-
NET LOSS		(1,891,543	)		(342,857	)		(2,407,059	)		(717,467	)
Less: Net loss (income) attributable to non controlling interest		(234	)		7,131			9,358			5,997
NET LOSS ATTRIBUTABLE TO APPLIED BIOSCIENCES CORP.	$	(1,891,777	)	$	(335,726	)	$	(2,397,701	)	$	(711,470	)

LOSS PER COMMON SHARE	$	(0.16	)	$	(0.02	)	$	(0.22	)	$	(0.05	)

WEIGHTED AVERAGE SHARES OUTSTANDING
Basic and diluted		11,797,297			15,595,100			11,150,168			15,458,775

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

Table of Contents

APPLIED BIOSCIENCES CORP.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

FOR THE NINE MONTHS ENDED DECEMBER 31, 2018 (UNAUDITED)

	Common Stock $0.00001 Par				Common Stock to be			Additional Paid In		Non- Controlling			Accumulated			Stockholders'
	Number		Amount		Issued			Capital		Interest			Deficit			Equity

Balance, March 31, 2018		10,499,610	$	105	$	526,000		$	3,054,297	$	(9,027	)	$	(2,901,933	)	$	669,442
Issuance of common stock previously committed but not issued		50,000		1		(100,000	)		99,999								-
Issuance of common stock for cash						75,000											75,000
Fair value of shares issued to consultant for services		90,000		1		45,926			179,999								225,926
Fair value of shares issued to advisory board member		25,000		-					51,000								51,000
Beneficial conversion feature associated with issuance of convertible notes									28,705								28,705
Net loss											(6,256	)		(395,501	)		(401,757	)
Balance, June 30, 2018 (unaudited)		10,664,610		107		546,926			3,414,000		(15,283	)		(3,297,434	)		648,316
Issuance of common stock for cash		12,500				(25,000	)		25,000								-
Fair value of shares issued to consultant for services						15,926			-								15,926
Beneficial conversion feature associated with issuance of convertible notes									99,900								99,900
Net loss											(3,336	)		(110,423	)		(113,759	)
Balance, September 30, 2018 (unaudited)		10,677,110		107		537,852			3,538,900		(18,619	)		(3,407,857	)		650,383
Fair value of shares issued to consultants for services		295,000		3		-			356,447								356,450
Fair value of shares issued to Company Officers and board member		625,000		6					756,244								756,250
Beneficial conversion feature associated with a convertible note									309,200								309,200
Conversion of convertible debt						1,444,500			-								1,444,500
Net loss											234			(1,891,777	)		(1,891,543	)
Balance, December 31, 2018 (unaudited)		11,597,110	$	116	$	1,982,352		$	4,960,791	$	(18,385	)	$	(5,299,634	)	$	1,625,240

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

Table of Contents

APPLIED BIOSCIENCES CORP.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

FOR THE NINE MONTHS ENDED DECEMBER 31, 2017 (UNAUDITED)

	Common Stock $0.00001 Par				Common Stock to be		Additional Paid In		Non- Controlling			Accumulated			Stockholders'
	Number		Amount		Issued		Capital		Interest			Deficit			Equity

Balance, March 31, 2017		15,247,600	$	152	$	426,000	$	1,742,472	$	1,736		$	(525,832	)	$	1,644,528
Common stock to be issued in conjunction with consulting agreement						50,000										50,000
Net income (loss)										1,196			(198,400	)		(197,204	)
Balance, June 30, 2017 (unaudited)		15,247,600		152		476,000		1,742,472		2,932			(724,232	)		1,497,324
Issuance of common stock for cash		347,500		2				694,998								695,000
Net income (loss)										(57	)		(177,350	)		(177,407	)
Balance, September 30, 2017 (unaudited)		15,595,100		154		476,000		2,437,470		2,875			(901,582	)		2,014,917
Common stock to be issued in conjunction with consulting agreement						62,333										62,333
Net income (loss)										(7,136	)		(335,720	)		(342,856	)
Balance, December 31, 2017 (unaudited)		15,595,100	$	154	$	538,333	$	2,437,470	$	(4,261	)	$	(1,237,302	)	$	1,734,394

The accompanying notes are an integral part of these condensed consolidated financial statements.

7

Table of Contents

APPLIED BIOSCIENCES CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Nine Months			Nine Months
	Ended			Ended
	December 31, 2018			December 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES	(unaudited)			(unaudited)

Net loss	$	(2,407,059	)	$	(717,467	)
Adjustment to reconcile net loss to net cash used in operating activities:
Unrecognized gain on equity investments		(404,763	)		-
Amortization of debt discount		437,805			-
Fair value of shares issued to consultants		649,302			112,333
Fair value of shares issued to officers and board member		756,250			-
Depreciation		878			44
Amortization of intangible		-			168,384
Changes in operating assets and liabilities
Accounts receivable		(5,436	)		992
Inventory		(41,031	)		(12,305	)
Prepaid and other current assets		77,699			12,630
Other asset		-			(5,500	)
Accounts payable and accrued expenses		147,492			20,188
Net cash used in operating activities		(788,863	)		(420,701	)

CASH FLOWS FROM INVESTING ACTIVITIES
Deposit on acquisition		(550,000	)		-
Acquisition of equity investments		-			(68,537	)
Purchase of property and equipment		-			(1,568	)
Net cash used in investing activities		(550,000	)		(70,105	)

CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from issuance of convertible notes		1,444,500			-
Proceeds from issuance of common stock		75,000			695,000
Net cash provided by financing activities		1,519,500			695,000

NET CHANGE IN CASH		180,637			204,194

CASH, BEGINNING OF PERIOD		60,934			212,637

CASH, END OF PERIOD	$	241,571		$	416,831

NON-CASH INVESTING AND FINANCING ACTIVITIES
Fair value of common stock issued upon conversion of convertible notes	$	1,444,500		$	-
Fair value of beneficial conversion feature related to issuance of convertible notes	$	437,805		$	-

The accompanying notes are an integral part of these condensed consolidated financial statements.

8

Table of Contents

NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Description of the Company

Applied BioSciences Corp. (formerly First Fixtures, Inc. and Stony Hill Corp. or the “Company”) was incorporated in the State of Nevada on February 21, 2014 and established a fiscal year end of March 31. Effective October 24, 2016 the Company changed its name from First Fixtures Inc. to Stony Hill Corp and on March 6, 2018, the Company changed its name from Stony Hill Corp. to Applied BioSciences Corp. The Company is focused on multiple areas of the hemp and CBD industry. Specifically, the Company is focused on select investments, branding, real estate, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

Basis of presentation – Unaudited Financial Statements

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the rules and regulations of the Securities and Exchange Commission. Accordingly, the unaudited condensed consolidated financial statements do not include all information and footnotes required by accounting principles generally accepted in the United States of America for complete annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of only normal recurring adjustments, considered necessary for a fair presentation. Interim operating results are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2019, or for any other interim period. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements as of and for the year ended March 31, 2018, which are included in the Company’s Report on Form 10-K for such year filed on June 28, 2018.

Going concern

These condensed statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. As reflected in the condensed consolidated financial statements, the Company incurred a net loss of $2,407,059 and used $788,863 of cash in operating activities during the nine months ended December 31, 2018. Further, the Company’s independent auditor in their audit report for fiscal year ended March 31, 2018 expressed substantial doubt about the Company’s ability to continue as a going concern. These and other factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

The Company’s ability to continue as a going concern is dependent upon its ability to raise additional capital and to ultimately achieve sustainable revenues and income from operations. During the nine months ended December 31, 2018, the Company sold 37,500 shares of its common stock to accredited investors at a price of $2.00 per share for total proceeds of $75,000 and issued convertible notes for total proceeds of $1,444,500 both in private placements to accredited investors. However, the Company will need and is currently working on obtaining additional funds to operate its business through and beyond the date of this Form 10-Q filing. There is no assurance that such funds will be available or at terms acceptable to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions and covenants on its operations, in the case of debt financing or cause substantial dilution for its stockholders in the case of convertible debt and equity financing.

9

Table of Contents

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Applied Products LLC, VitaCBD LLC, an 80% owned entity, both Washington limited liability companies and SHL Management LLC, a Nevada limited liability company. Intercompany transactions and balances have been eliminated in consolidation. Management evaluates its investments on an individual basis for purposes of determining whether or not consolidation is appropriate.

Use of Estimates and Assumptions

Preparation of the condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Among other things, management estimates include the collectability of its accounts receivable, recoverability of inventory, assumptions made in determining impairment of investments and intangible assets, accruals for potential liabilities, and realization of deferred tax assets. These estimates generally involve complex issues and require judgments, involve analysis of historical information and the prediction of future trends, and are subject to change from period to period. Actual amounts could differ significantly from these estimates.

Revenue Recognition

The Company adopted the guidance of ASC 606 on April 1, 2018, Revenue from Contracts with Customers (Topic 606), (ASC 606). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (1) identifying the contract(s) or agreement(s) with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied.

Under ASC 606, revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products or services to our customers based on written sales terms, which is also when control is transferred. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products or services to a customer.

The implementation of ASC 606 had no impact on the condensed consolidated financial statements and no cumulative effect adjustment was recognized.

Advertising

The Company expenses advertising costs as incurred. Advertising expense for the three and nine months ended December 31, 2018 amounted to $100,730 and $556,167, respectively, and $165,315 and $229,674 for the three and nine months ended December 31, 2017 and are included in "Sales and Marketing expenses" in the Condensed Consolidated Statements of Operations.

10

Table of Contents

Earnings (Loss) per Share

The basic earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Shares of common stock to be issued are included in weighted average shares calculation from the date of grant. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the period. The diluted weighted average number of shares outstanding is the basic weighted average number of shares adjusted for any potentially dilutive debt or equity. Diluted earnings (loss) per share are the same as basic earnings (loss) per share due to the lack of dilutive items.

Investments

Through March 31, 2018, the Company used either the equity method or the cost method of accounting. The Company used the equity method for unconsolidated equity investments in which the Company was considered to have significant influence over the operations of the investee. The Company used the cost method for all other investments. Under the cost method, there is no change to the cost basis unless there is an other-than-temporary decline in value or dividends are received. If the decline is determined to be other-than-temporary, the Company writes down the cost basis of the investment to a new cost basis that represents realizable value.

On April 1, 2018, the Company adopted ASU 2016-01, Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 primarily affects equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. Among other things, this new guidance requires certain equity investments to be measured at fair value with changes in fair value recognized in net income. As such, the Company measures its equity investments at their fair value at end of each reporting period.

Investments accounted for under the equity method or cost method of accounting above are included in the caption "Equity investments" on the Condensed Consolidated Balance Sheets.

Recent Accounting Pronouncements

In February 2016, the FASB issued ASU No. 2016-02, Leases. This update will require the recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, for all leases with terms longer than 12 months. For operating leases, the asset and liability will be expensed over the lease term on a straight-line basis, with all cash flows included in the operating section of the statement of cash flows. For finance leases, interest on the lease liability will be recognized separately from the amortization of the right-of-use asset in the statement of comprehensive income and the repayment of the principal portion of the lease liability will be classified as a financing activity while the interest component will be included in the operating section of the statement of cash flows. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018. Early adoption is permitted. Upon adoption, leases will be recognized and measured at the beginning of the earliest period presented using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its financial statements and related disclosures.

In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” The ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The ASU also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Revenue from Contracts with Customers (Topic 606). The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. The Company is currently assessing the effect that the ASU will have on our financial position, results of operations, and disclosures.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

11

Table of Contents

NOTE 3 – INVESTMENT

Equity investments relate to purchases of stock in certain entities with ownership percentages of less than 5%. As of March 31, 2018, these investments were recorded at their cost basis. On April 1, 2018, the Company adopted ASU 2016-01, Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities, and as such, these investments were recorded at their market value as of December 31, 2018. The investments consist of the following:

	December 31, 2018		March 31, 2018
(A) Cannabi-Tech Ltd. (Gemma)	$	68,537	$	68,237
(B) Hightimes Holdings Corp.		654,763		250,000
(C) Precision Cultivation Systems, LLC		50,000		50,000
(D) Bailey Venture Partners XII LLC (JUUL)		100,000		100,000
	$	873,300	$	468,537

(A) In November 2016, the Company purchased 29,571 shares of Preferred A stock of Cannabi-Tech Ltd. (“Cannabi”), at a price of $1.69086 per share for total investment of $50,000. In October 2017, the Company purchased 7,309 shares of Preferred A-1 stock of Cannabi at a price of $2.536 per share for total investment of $18,537. As of March 31, 2018, total investment amounted to $68,537, which accounts for less than 5% in Cannabi. Cannabi is a private company incorporated in the State of Israel that provides lab-grade medical cannabis quality control testing systems used to test the quality of medical marijuana flowers. The fair value of the investment at December 31, 2018 approximated its cost basis.

(B) In January 2017, the Company entered in to an agreement to purchase 59,524 shares of Class A common stock at a price of $4.20 per share for total investment of $250,000, which accounts for less than 5% investment in Hightimes Holdings Corp. (“Hightimes”). Hightimes owns Hight Times Magazine and hosts festivals, events and competitions including the High Times Cannabis Cup and multiple e-commerce properties, including HighTimes.com, CannabisCup.com and 420.com. As of September 30, 2018 and December 31, 2018, the Company was able to obtain observable evidence that the investment had a market value of $11.00 per share, or an aggregate value of $654,763. As such, the Company recorded an unrecognized gain from the change in market value of $404,763 during the nine months ended December 31, 2018.

(C) In June 2017, the Company entered in a Subscription Agreement to purchase 0.5% interest in Precision Cultivation Systems, LLC (“Precision”), a Delaware limited liability company, for a purchase price of $50,000. Precision is developing a growth system that capitalizes on a patent-pending cultivation method that utilizes proprietary irrigation and root zone conditioning. As part of the Subscription Agreement, $42,500 of the investment is subject to repayment on a pro-rata basis with other investors who have entered into similar Subscription Agreements. Amounts subject to repayment are solely at the discretion of Precision. The fair value of the investment at December 31, 2018 approximated its cost basis.

(D) In January 2018, the Company paid $100,000 for the purchase of a Membership Interest in Bailey Venture Partners XII LLC (“Bailey”) representing less than 5% interest in Bailey. Along with other funds received from third-party investors, Bailey plans to invest funds received in various strategic investments. The Company recorded this investment at cost and will recognize dividends, if any, when received, and will recognize gains or loss upon either selling the securities or recognize a loss prior to selling the securities if there is evidence that the fair market value of the investment has declined to below the recorded historical cost. The fair value of the investment at December 31, 2018 approximated its cost basis.

In February 2019, the Company received a distribution of approximately $186,000 from Bailey’s investment in JUUL Labs, Inc.

As the Company does not participate in the management of these companies nor has the ability to exercise significant influence over these companies, the Company recorded these investments at cost, and as of April 1, 2018, will adjust the cost basis to market at the end of each reporting period. Dividends, if any, will be recognized when received.

During the three months ended December 31, 2018, the Company paid $550,000 as a deposit towards the acquisition purchase price of Trace Analytics, Inc. (see Note 7), which was reflected as deposit on the acquisition in the accompanying condensed consolidated balance sheet as of the period then ended.

12

Table of Contents

NOTE 4 – CONVERTIBLE NOTE

During the nine months ended December 31, 2018, the Company issued separate Convertible Promissory Notes (“Notes”) having a total principal amount of $1,444,500 to certain accredited holders. All outstanding principal together with interest on these Notes was due and payable on December 31, 2018 and accrued interest ranging from 1% to 8% per month, and 8% per annum. The note holders, at their sole discretion and election, were allowed to convert any part or all of the then outstanding principal and/or interest on these Notes into shares of common stock of the Company at a fixed price per share of $1.00. On December 31, 2018, all holders of the Notes converted the principal portion of their Notes to 1,444,500 shares of the Company’s common stock. The shares had not been issued as of December 31, 2018 and were reflected in “Common stock to be issued” in the condensed consolidated statement of stockholders’ equity during the period then ended.

A portion of the Notes with principal amount aggregating $1,019,500 were issued when the market price of the Company’s common stock was in excess of the $1.00 per share conversion price creating beneficial conversion feature associated with these Notes with an aggregate amount of $437,805 upon issuance dates. As such, the Company recorded $437,805 in additional paid-in capital and debt discount representing the intrinsic value of the beneficial conversion feature at the date of the borrowing against the Notes. The value of the beneficial conversion feature was fully amortized upon conversion of all of the outstanding Notes and reflected as interest expense for the nine months ended December 31, 2018.

NOTE 5 – RELATED PARTY TRANSACTIONS

In view of the Company’s limited operations and resources, none of the Company’s directors and/or officers received any compensation from the Company during the nine months ended December 31, 2018 and 2017.

NOTE 6 – EQUITY

Common Stock to be Issued

On February 23, 2017, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with mCig, Inc., a Nevada corporation (“mCig”) consisting of the issuance of an aggregate of 350,000 shares of common stock. Of the 350,000 shares of common stock consideration, 150,000 shares or $426,000 were not issued as of March 31, 2018 and were included in “Common stock to be issued” in the accompanying condensed consolidated statement of stockholders’ equity. During the nine months ended December 31, 2018, the Company issued 50,000 shares of common stock valued at $100,000 which was previously reflected as “Common stock to be issued” in the condensed consolidated statement of stockholders’ equity.

During the nine months ended December 31, 2018, the Company sold 37,500 shares of common stock, of which 25,000 shares had not been issued as of December 31, 2018 and is reflected in “Common stock to be issued” in the condensed consolidated statement of stockholders’ equity. The shares were sold at a price of $2.00 per share for total proceeds of $75,000 pursuant to a private placement Subscription Agreement with accredited investors. The Subscription Agreement offered up to one million shares of the Company’s common stock at a price per share of $2.00 per share. The Company made this offering solely to accredited investors, as defined under Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended.

Establishment of Advisory Board and Adoption of Charter

On April 28, 2017, the Company established an advisory board (the “Advisory Board”) and approved and adopted a charter (the “Advisory Board Charter”) to govern the Advisory Board. The Advisory Board shall be comprised of one or more directors (“Advisors”), and up to nine independent, non-Board, non-employee members, all of whom shall be appointed and subject to removal by the Board of Directors at any time.

During the nine months ended December 31, 2018, the Company appointed an advisor to the Advisory Board, which entitled him to an annual consulting fee 25,000 shares of the Company’s stock for a term of 6 months, with total fair value of $51,000.

13

Table of Contents

Shares issued to consultants for services

During the nine months ended December 31, 2018, the Company granted an aggregate of 414,815 shares of its common stock to seven (7) consultants as payment for services rendered to the Company and recorded expense of $598,302 based on the fair value of the Company’s common stock at grant dates. Of the 414,815 shares granted, 29,815 shares valued at $61,852 had not been issued as of December 31, 2018 and were reflected in “Common stock to be issued” in the condensed consolidated statement of stockholders’ equity during the period then ended.

Shares issued to officers and directors for compensation

During the nine months ended December 31, 2018, the Company granted an aggregate of 625,000 shares of its common stock to one (1) board member and (2) officers of the Company as payment for services rendered to the Company and recorded expense of $756,250 based on the fair value of the Company’s common stock at grant dates.

NOTE 7 – SUBSEQUENT EVENTS

Acquisition

On January 1, 2019, the Company entered into a Common Stock Purchase Agreement and closed on a purchase of 520,410 shares of common stock of Trace Analytics, Inc., a Washington corporation (“Trace Analytics”), at a purchase price of $2.40 per share, for an aggregate purchase price of $1,250,000, of which $750,000 was payable in cash and $500,000 of which will be paid in shares of common stock of the Company. During the three months ended December, 31, 2018, the Company paid $550,000 towards the acquisition purchase price of Trace Analytics, and which was reflected as deposit on the acquisition of Trace Analytics in the accompanying condensed consolidated balance sheet as of the period then ended. Immediately following the purchase, the Company holds 51% of the issued and outstanding shares of common stock of Trace Analytics. The Company is in the process of analizing the accounting effects of this transaction and historical financial statements of the acquired company and pro forma effects of the acquisition will be provided in a Form 8K/A to be subsequently filed.

On February 6, 2019, the Company issued an aggregate of 250,000 shares of common stock of the Company as payment for the shares of common stock payable to Trace Analytics. 125,000 of such shares were issued directly to Jason Zitzer, and 125,000 of such shares were issued directly to Gordon Fargas, both of whom are affiliates of Trace Analytics.

Trace Analytics is a cannabis testing laboratory and service company located in Spokane, Washington. Some of the services provided by Trace Analytics are:

· 502 compulsory testing for all types of cannabis products;

· Industrial hemp CBD product testing;

· Extensive terpene, residual solvents, and cannabinoid profiles;

· Aflatoxin/Mycotoxin screening;

· Experienced grow consultation, evaluation and related services; and

· Edibles work up, process evaluation and dose distribution guidance.

In connection with the Common Stock Purchase Agreement, the Company also entered into a Stockholders’ Agreement (the “Stockholders’ Agreement”), dated January 1, 2019, with Trace Analytics, Jason Zitzer, and Gordon Fargas. Mr. Zitzer and Mr. Fargas are affiliates of Trace Analytics and the only other stockholders of Trace Analytics, in addition to the Company. The Stockholders’ Agreement contains certain transfer restrictions and a right of first refusal which provides that if any party to the Stockholder’s Agreement proposes to transfer its Trace Analytics shares, Trace Analytics shall for a period of 30 days, have a first right of refusal to purchase such shares, followed by a first right of refusal for the remaining shareholders.

In connection with the Common Stock Purchase Agreement, the Company also entered into a Voting Agreement (the “Voting Agreement”), dated January 1, 2019, with Trace Analytics, Jason Zitzer, and Gordon Fargas. The Voting Agreement provides that the parties of the Voting Agreement shall vote their shares of common stock of Trace Analytics to appoint the three of the five members of the board of directors of Trace Analytics as designated by the Company, one member of the board of directors as designated by Mr. Ziter, and one member of the board of directors as designated by Mr. Fargas

Distribution

In February 2019, the Company received a distribution of approximately $186,000 from Bailey's investment in JUUL Labs, Inc.

14

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This section of this Form 10-Q includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our predictions.

Results of Operations

Our revenue, operating expenses, and net loss from operations for our three and nine months ended December 31, 2018 as compared to our three and nine months ended December 31, 2017 were as follows:

Three Months Ended December 31, 2018 Compared to Three Months Ended December 31, 2017

	Three Months Ended December 31, 2018			Three Months Ended December 31, 2017			$ Change Inc (Dec)			Percentage Change Inc (Dec)

PRODUCT REVENUE, NET	$	413,109		$	62,977		$	350,132			556	%

COST OF REVENUE, PRODUCT		379,582			50,370			329,212			654	%

GROSS MARGIN		33,527			12,607			20,920			166	%

EXPENSES
Sales and marketing		100,730			165,315			(64,585	)		(39	)%
General and administrative		1,317,469			133,977			1,183,492			883	%
Depreciation and Amortization		292			56,172			(55,880	)		(99	)%
TOTAL OPERATING EXPENSES		1,418,491			355,464			1,063,027			299	%
OPERATING LOSS		(1,384,964	)		(342,857	)		1,042,107			304	%
Other Income (Expense)
Interest Expense		(506,579	)		-			(506,579	)		-
Total other income, net		(506,579	)		-			(506,579	)		-
NET LOSS		(1,891,543	)		(342,857	)		1,548,686			452	%
Less: Net loss attributable to non controlling interest		(234	)		7,131			(7,365	)		(103	)%
NET LOSS ATTRIBUTABLE TO APPLIED BIOSCIENCES CORP.	$	(1,891,777	)	$	(335,726	)	$	1,556,051			463	%

Revenues: Revenue from products relate to shipments of cannabidiol (“CBD”) brand products. During the three months ended December 31, 2018, we earned revenue from our CBD product lines of $413,109 as compared to $62,977 for the three months ended December 31, 2017. The factors that contributed to the $350,132 increase in revenue were the $14,132 increase related to higher sales of our new Remedi CBD, HerbalPet, TherPet and CanaGel CBD products, which we launched during our current fiscal year, and the $336,000 increase related to our wholesale of industrial Hemp.

Cost of Goods Sold: Cost of goods sold consists of purchases of CBD product inventory for sale. During the three months ended December 31, 2018, we incurred $379,582 of costs related to product purchases as compared to $50,370 for the three months ended December 31, 2017. The increase of $329,212 reflects the product cost of our launch of new products during our current fiscal year and $300,000 purchase of industrial Hemp for wholesale.

Gross Margin: Gross margin comprised from our sale of products and was $33,527 or 8% of sales for the three months ended December 31, 2018 as compared to $12,607 or 20% of sales for the three months ended December 31, 2017. The increase of $20,920 reflects our increase in sales. The lower gross margin percentage mainly relates to 10.7% margin obtained from our wholesale of industrial Hemp.

15

Table of Contents

Sales and Marketing: Sales and marketing expenses mainly comprised of advertising, public relations, events, and website marketing costs. Sales and marketing expenses decreased $64,585 to $100,730 for the three months ended December 31, 2018 as compared to $165,315 for the three months ended December 31, 2017. The majority of the decrease related to lower public relation services, website marketing development and advertising and promotion costs.

General and Administrative: General and administrative expenses mainly comprised of professional fees, travel expenses, meals and entertainment and other office support costs. General and administrative expenses increased $1,183,492 to $1,317,469 for the three months ended December 31, 2018 as compared to $133,977 for the three months ended December 31, 2017. The majority of the increase related to non-cash issuance of our common stock to certain officers, advisory members and board members and consultants in exchange for services which totaled $1,133,534 for the three months ended December 31, 2018. The remaining amount of the increase related to higher professional and advisory fees and other supportive general and administrative expenses.

Depreciation and Amortization: Depreciation expense was $292 for the three months ended December 31, 2018 as compared to $56,172 for the three months ended December 31, 2017. The decrease relates to amortization during our three months ended December 31, 2017 related to a brand that we acquired in February 2017, which was fully expensed during our fiscal year ended March 31, 2018. We did not own any similar intangibles that required amortization during the three months ended December 31, 2018.

Interest Expense: During the three months ended December 31, 2018, we recorded $111,489 of interest costs related to convertible notes that we entered into during our current fiscal year along with amortization of $395,090 of debt discount recorded in conjunction with the convertible notes.

Nine months Ended December 31, 2018 Compared to Nine months Ended December 31, 2017

	Nine Months Ended December 31, 2018			Nine Months Ended December 31, 2017			$ Change Inc (Dec)			Percentage Change Inc (Dec)

PRODUCT REVENUE, NET	$	472,509		$	179,534		$	292,975			163	%

COST OF REVENUE, PRODUCT		439,740			140,706			299,034			213	%

GROSS MARGIN		32,769			38,828			(6,059	)		(16	)%

EXPENSES
Sales and marketing		556,167			229,674			326,493			142	%
General and administrative		1,712,667			358,193			1,354,474			378	%
Depreciation and Amortization		877			168,428			(167,551	)		(99	)%
TOTAL OPERATING EXPENSES		2,269,711			756,295			1,513,416			200	%
OPERATING LOSS		(2,236,942	)		(717,467	)		1,519,475			212	%
Other Income (Expense)
Unrecognized gain on equity investments		404,763			-			404,763			-
Interest Expense		(574,880	)		-			(574,880	)		-
Total other income, net		(170,117	)		-			(170,117	)		-
NET LOSS		(2,407,059	)		(717,467	)		1,689,592			235	%
Less: Net loss attributable to non controlling interest		9,358			5,997			3,361			56	%
NET LOSS ATTRIBUTABLE TO APPLIED BIOSCIENCES CORP.	$	(2,397,701	)	$	(711,470	)	$	1,686,231			237	%

Revenues: During the nine months ended December 31, 2018, we earned revenue from our CBD product lines of $472,509 as compared to $179,534 for the nine months ended December 31, 2017. The increase of $292,975 relates primarily to our wholesale of industrial Hemp for $336,000 offset by a decrease in our sale of CBD products primarily driven by our efforts to replace previously existing CBD products and change our product lines and branding to our new Remedi CBD, HerbalPet, TherPet and CanaGel CBD products. This required our change in marketing, branding, labeling and warehousing which ultimately caused sales to temporarily slow until we relaunched our new CBD products during our current fiscal year.

16

Table of Contents

Cost of Goods Sold: During the nine months ended December 31, 2018, we incurred $439,740 of costs primarily related to purchase of industrial Hemp for wholesale and product purchases and labeling of new products as compared to $140,706 for the nine months ended December 31, 2017.

Gross Margin: Gross margin comprised from our sale of products and was $32,769 or 7% of sales for the three months ended December 31, 2018 as compared to $38,828 or 22% of sales for the three months ended December 31, 2017. The decrease of $6,059 reflects our refocus and launch of new CBD products during our current fiscal year. The lower gross margin percentage mainly relates to 10.7% margin obtained from our wholesale of industrial Hemp.

Sales and Marketing: Sales and marketing expenses increased $326,493 to $556,167 for the nine months ended December 31, 2018 as compared to $229,674 for the nine months ended December 31, 2017. The majority of the increase related to stock compensation of $210,000 along with public relation services, website marketing development and increased advertising and promotion costs.

General and Administrative: General and administrative expenses increased $1,354,474 to $1,712,667 for the nine months ended December 31, 2018 as compared to $358,193 for the nine months ended December 31, 2017. The majority of the increase related to higher professional fees and general and administrative expenses. The majority of the increase related to non-cash issuance of our common stock to certain officers, advisory members and board members and consultants in exchange for services which totaled $1,271,959 for the six months ended December 31, 2018. The remaining amount of the increase related to higher professional and advisory fees and other supportive general and administrative expenses.

Depreciation and Amortization: Depreciation expense was $877 for the nine months ended December 31, 2018 as compared to $168,428 for the nine months ended December 31, 2017. The decrease relates to amortization during our nine months ended December 31, 2017 related to a brand that we acquired in February 2017, which was fully expensed during our fiscal year ended March 31, 2018. We did not own any similar intangibles that required amortization during the nine months ended December 31, 2018.

Unrecognized Gain on Equity Investments: During the nine months ended December 31, 2018, we were able to obtain observable evidence that an investment we own had increased by $6.80 per share for an aggregate value of $654,763, which was $404,763 higher than our original purchase price for this investment. As such, we recorded an unrecognized gain from the change in market value of $404,763 during the nine months ended December 31, 2018.

Interest Expense: During the nine months ended December 31, 2018, we recorded $137,075 of interest costs related to a convertible notes that we entered into during our current fiscal year along with amortization of $437,805 of debt discount recorded in conjunction with the convertible notes..

Liquidity and Capital Resources

Cash Flows

A summary of our cash flows for the nine months ended December 31, 2018 is as follows:

Net cash used in operating activities was $788,863 for the nine months ended December 31, 2018 as compared to $420,701 for the nine months ended December 31, 2017. The increase in use of cash in operations mainly related to higher general and administrative and sales and marketing expenses from our operations.

Net cash used in investing activities during the nine months ended December 31, 2018 was the $550,000 deposit on the purchase price related to the acquisition of Trace Analytics, Inc., which was completed in January 2019 as compared to $70,105 during the nine months ended December 31, 2017, which mainly comprised of a $68,537 equity investment we made during that period.

Net cash provided by financing activities for the nine months ended December 31, 2018 was $1,519,500 as compared to $695,000 for the nine months ended December 31, 2017. The amounts received during our nine months ended December 31, 2018 related to $75,000 from proceeds from the sale of shares of our common stock and $1,444,500 received from our issuance of convertible notes. The amounts received during our nine months ended December 31, 2017 related to our issuance of our common stock for cash.

17

Table of Contents

Going Concern

As reflected in the condensed consolidated financial statements contained elsewhere is this Form 10-Q, as of December 31, 2018 we had cash on hand and had an accumulated deficit of $241,571 and $5,299,634, respectively, and during the nine months ended December 31, 2018, we utilized cash for operations and incurred a net loss of $788,863 and $2,407,059, respectively. Our uses of cash have been primarily for strategic investments we made and operations and marketing efforts to promote and develop our CBD products and our company. Our principal sources of liquidity have been cash provided by financing, primarily through the sale of equity securities and issuance of convertible notes, along with revenues from our principal business activities. Further, we have used cash for various strategic investments for which we typically receive returns when such investments are sold and when or if dividends are declared.

As of the date of this Form 10-Q, our cash resources are insufficient to meet our current operating expense requirements and planned business objectives without additional financing. Our ability to continue as a going concern is dependent on our ability to raise additional capital and to ultimately achieve sustainable revenues and income from our operations. During the nine months ended December 31, 2018, we raised $75,000 through the receipt of Subscription Agreements (“Subscription”) where we sold 37,500 shares of our common stock to accredited investors at a price of $2.00 per share. We also received during the nine months ended December 31, 2018 $1,444,500 from the issuance of convertible notes to accredited investors. However, we anticipate that significant additional expenditures will be necessary to expand and bring to market our products and investments before sufficient and consistent positive operating cash flows will be achieved. As such, we will need additional funds to operate our business through and beyond the date of this Form 10-Q filing. There can be no assurance that such funds will be available or at terms acceptable to us. Even if we are able to obtain additional financing, it may contain undue restrictions and covenants on our operations, in the case of debt financing or cause substantial dilution for our stockholders in the case of convertible debt and equity financing.

These and other factors raise substantial doubt about our ability to continue as a going concern. Further, our independent auditors in their audit report for our fiscal year ended March 31, 2018 expressed substantial doubt about our ability to continue as a going concern. Our financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern.

Summary of Significant Accounting Policies

Use of Estimates

Preparation of the condensed consolidated financial statements in conformity with generally accepted accounting principles requires us to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Among other things, our estimates include the collectability of our accounts receivable, recoverability of inventory, assumptions made in determining impairment of investments and intangible assets, accruals for potential liabilities, and realization of deferred tax assets. These estimates generally involve complex issues and require judgments, involve analysis of historical information and the prediction of future trends, and are subject to change from period to period. Actual amounts could differ significantly from these estimates.

Investments

We used either the equity method or the cost method of accounting. We use the equity method for unconsolidated equity investments in which we are considered to have significant influence over the operations of the investee. We use the cost method for all other investments. Under the cost method, there is no change to the cost basis unless there is an other-than-temporary decline in value or dividends are received. If the decline is determined to be other-than-temporary, we write down the cost basis of the investment to a new cost basis that represents realizable value.

18

Table of Contents

On April 1, 2018 we adopted ASU 2016-01, Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 primarily affects equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. Among other things, this new guidance requires certain equity investments to be measured at fair value with changes in fair value recognized in net income. As such, we measure our equity investments at their fair value at end of each reporting period.

Investments accounted for under the equity method or cost method of accounting above are included in the caption "Equity investments" in our Condensed Consolidated Balance Sheets.

Recent Accounting Pronouncements

See our discussion of recent accounting policies in Footnote 2 to the condensed consolidated financial statements contained elsewhere in this Form 10-Q.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time period specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is accumulated and communicated to management including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure.

In connection with this quarterly report, as required by Rule 15d-15 under the Securities Exchange Act of 1934, we have carried out an evaluation of the effectiveness of the design and operation of our company's disclosure controls and procedures. This evaluation was carried out under the supervision and with the participation of our company's management, including our company's principal executive officer and principal financial officer. Based upon that evaluation, our company's principal executive officer and principal financial officer concluded that as of December 31, 2018, our disclosure controls and procedures were not effective.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) or 15d-15(f)) during the nine months ended December 31, 2018 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

19

Table of Contents

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

Currently we are not subject to any pending litigation or legal proceeding.

Item 1A. Risk Factors.

As a smaller reporting company as defined by Rule 12b-2 of the Exchange Act we are not required to provide the information required under this item.

Item 2. Unregistered Sales of Securities and Use of Proceeds.

Not applicable

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

None.

Item 5. Other Information.

None.

20

Table of Contents

Item 6. Exhibits.

(a) Exhibits required by Item 601 of Regulation SK.

Number		Description

2.1		Share Exchange Agreement, dated November 4, 2016, by and among the Applied Biosciences Corp., Stony Hill Ventures Corp., a Nevada corporation, and the holders of common stock of Stony Hill Ventures Corp. (3)

3.1.1		Articles of Incorporation (1)

3.1.2		Certificate of Amendment (3)

3.1.3		Certificate of Change (3)

3.1.4		Certificate of Amendment (4)

3.2		Bylaws (2)

31.1		Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS *

XBRL Instance Document

101.SCH *

XBRL Taxonomy Extension Schema Document

101.CAL *

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF *

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB *

XBRL Taxonomy Extension Label Linkbase Document

101.PRE *

XBRL Taxonomy Extension Presentation Linkbase Document

____________

(1)

Incorporated by reference to the Registrant’s Registration Statement on Form S-1 (File No. 333-197443), filed with the Securities and Exchange Commission on July 16, 2014.

(2)

Incorporated by reference to the Registrant's Registration Statement on Form S-1/A (File No. 333-197443), filed with the Securities and Exchange Commission on October 16, 2014.

(3)

Incorporated by reference to the Registrant’s Current Report on Form 8-K (File No. 000-52223), filed with the Securities and Exchange Commission on November 10, 2016.

(4)

Incorporated by reference to the Registrant’s Current Report on Form 8-K (File No. 000-52223) filed with the Securities Exchange Commission on March 5, 2018

*

XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

21

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	APPLIED BIOSCIENCES CORP.
	(Name of Registrant)

Date: February 13, 2019	By:	/s/ Chris Bridges
	Name:	Chris Bridges
	Title:	President (principal executive officer)

Date: February 13, 2019	By:	/s/ John James Southard
	Name:	John James Southard
	Title:	Secretary and Treasurer (principal accounting officer and financial officer)

EX-31.1 2 appb_ex311.htm CERTIFICATION appb_ex311.htm

EXHIBIT 31.1

SECTION 302 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER OF APPLIED BIOSCIENCES CORP.

I, Chris Bridges, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Applied Biosciences Corp.;

2.	Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3.	Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 13, 2019	By:	/s/ Chris Bridges
		Chris Bridges
		President (principal executive officer)

EX-31.2 3 appb_ex312.htm CERTIFICATION appb_ex312.htm

EXHIBIT 31.2

SECTION 302 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF APPLIED BIOSCIENCES CORP.

I, John James Southard, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Applied Biosciences Corp.;

2.	Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3.	Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 13, 2019	By:	/s/ John James Southard
		John James Southard
		Secretary (principal accounting officer and principal financial officer)

EX-32.1 4 appb_ex321.htm CERTIFICATION appb_ex321.htm

EXHIBIT 32.1

SECTION 906 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER OF APPLIED BIOSCIENCES CORP.

In connection with the accompanying Quarterly Report on Form 10-Q of Applied Biosciences Corp. for the nine months ended December 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Chris Bridges, President of Applied Biosciences Corp., does hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

	(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Applied Biosciences Corp.

Date: February 13, 2019	By:	/s/ Chris Bridges
		Chris Bridges
		President
		(principal executive officer)

EX-32.2 5 appb_ex322.htm CERTIFICATION appb_ex322.htm

EXHIBIT 32.2

SECTION 906 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF APPLIED BIOSCIENCES CORP.

In connection with the accompanying Quarterly Report on Form 10-Q of Applied Biosciences Corp. for the nine months ended December 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, John James Southard, Secretary of Applied Biosciences Corp., does hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

	(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Applied Biosciences Corp.

Date: February 13, 2019	By:	/s/ John James Southard
		John James Southard
		Secretary and Treasurer
		(principal accounting officer and principal financial officer)

EX-101.INS 6 appb-20181231.xml XBRL INSTANCE DOCUMENT 0001607549 2018-04-01 2018-12-31 0001607549 2019-02-08 0001607549 2018-03-31 0001607549 2018-12-31 0001607549 us-gaap:SeriesAPreferredStockMember 2016-11-30 0001607549 us-gaap:CommonStockMember 2017-03-31 0001607549 appb:CommonStockToBeIssuedMember 2017-03-31 0001607549 us-gaap:AdditionalPaidInCapitalMember 2017-03-31 0001607549 us-gaap:NoncontrollingInterestMember 2017-03-31 0001607549 us-gaap:RetainedEarningsMember 2017-03-31 0001607549 us-gaap:CommonClassAMember 2017-01-31 0001607549 appb:CannabTechLtdMember 2018-03-31 0001607549 appb:HightimesHoldingsCorpMember 2018-03-31 0001607549 us-gaap:CommonStockMember 2017-04-01 2017-06-30 0001607549 us-gaap:CommonStockMember 2017-06-30 0001607549 appb:CommonStockToBeIssuedMember 2017-04-01 2017-06-30 0001607549 appb:CommonStockToBeIssuedMember 2017-06-30 0001607549 us-gaap:AdditionalPaidInCapitalMember 2017-04-01 2017-06-30 0001607549 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0001607549 us-gaap:NoncontrollingInterestMember 2017-04-01 2017-06-30 0001607549 us-gaap:NoncontrollingInterestMember 2017-06-30 0001607549 us-gaap:RetainedEarningsMember 2017-04-01 2017-06-30 0001607549 us-gaap:RetainedEarningsMember 2017-06-30 0001607549 appb:PrecisionCultivationSystemsLLCMember 2017-06-30 0001607549 appb:PrecisionCultivationSystemsLLCMember 2017-06-01 2017-06-30 0001607549 appb:MCigLLCMember 2017-02-23 0001607549 appb:PrecisionCultivationSystemsLLCMember 2018-03-31 0001607549 2017-04-01 2017-06-30 0001607549 us-gaap:CommonStockMember 2017-09-30 0001607549 appb:CommonStockToBeIssuedMember 2017-09-30 0001607549 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0001607549 us-gaap:NoncontrollingInterestMember 2017-09-30 0001607549 us-gaap:RetainedEarningsMember 2017-09-30 0001607549 us-gaap:CommonStockMember 2017-12-31 0001607549 appb:CommonStockToBeIssuedMember 2017-12-31 0001607549 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001607549 us-gaap:NoncontrollingInterestMember 2017-12-31 0001607549 us-gaap:RetainedEarningsMember 2017-12-31 0001607549 us-gaap:SeriesAPreferredStockMember 2016-11-01 2016-11-30 0001607549 us-gaap:SeriesAPreferredStockMember 2017-10-31 0001607549 us-gaap:SeriesAPreferredStockMember 2017-10-02 2017-10-31 0001607549 us-gaap:CommonClassAMember 2017-01-02 2017-01-31 0001607549 us-gaap:CommonStockMember 2018-03-31 0001607549 appb:CommonStockToBeIssuedMember 2018-03-31 0001607549 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001607549 us-gaap:NoncontrollingInterestMember 2018-03-31 0001607549 us-gaap:RetainedEarningsMember 2018-03-31 0001607549 appb:BaileyVenturePartnersXIILLCMember 2018-03-31 0001607549 appb:BaileyVenturePartnersXIILLCMember 2018-01-31 0001607549 appb:CannabiTechLtdMember 2018-03-31 0001607549 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001607549 us-gaap:CommonStockMember 2018-06-30 0001607549 appb:CommonStockToBeIssuedMember 2018-04-01 2018-06-30 0001607549 appb:CommonStockToBeIssuedMember 2018-06-30 0001607549 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001607549 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001607549 us-gaap:NoncontrollingInterestMember 2018-04-01 2018-06-30 0001607549 us-gaap:NoncontrollingInterestMember 2018-06-30 0001607549 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001607549 us-gaap:RetainedEarningsMember 2018-06-30 0001607549 2017-03-31 0001607549 2017-06-30 0001607549 appb:AppliedProductsLLCMember appb:VitaCBDLLCMember 2018-04-01 2018-12-31 0001607549 appb:CannabTechLtdMember 2018-12-31 0001607549 appb:HightimesHoldingsCorpMember 2018-12-31 0001607549 appb:PrecisionCultivationSystemsLLCMember 2018-12-31 0001607549 appb:BaileyVenturePartnersXIILLCMember 2018-12-31 0001607549 appb:ConvertiblePromissoryNotesMember 2018-12-31 0001607549 appb:ConvertiblePromissoryNotesMember 2018-04-01 2018-12-31 0001607549 appb:BaileyVenturePartnersXIILLCMember 2018-01-01 2018-01-31 0001607549 2017-04-01 2017-12-31 0001607549 2017-10-01 2017-12-31 0001607549 2018-10-01 2018-12-31 0001607549 2017-09-30 0001607549 appb:CannabiTechLtdMember 2018-03-01 2018-03-31 0001607549 us-gaap:CommonStockMember 2018-09-30 0001607549 appb:CommonStockToBeIssuedMember 2018-09-30 0001607549 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001607549 us-gaap:NoncontrollingInterestMember 2018-09-30 0001607549 us-gaap:RetainedEarningsMember 2018-09-30 0001607549 us-gaap:InvestorMember 2018-04-01 2018-12-31 0001607549 appb:ConsultingAgreementMember appb:SevenConsultantsMember 2018-12-31 0001607549 us-gaap:SubsequentEventMember 2018-12-25 2019-01-01 0001607549 appb:AssetPurchaseAgreementMember 2018-04-01 2018-12-31 0001607549 appb:AdvisoryBoardMember 2018-04-01 2018-12-31 0001607549 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001607549 us-gaap:CommonStockMember 2018-10-01 2018-12-31 0001607549 us-gaap:CommonStockMember 2018-12-31 0001607549 appb:CommonStockToBeIssuedMember 2018-07-01 2018-09-30 0001607549 appb:CommonStockToBeIssuedMember 2018-10-01 2018-12-31 0001607549 appb:CommonStockToBeIssuedMember 2018-12-31 0001607549 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001607549 us-gaap:AdditionalPaidInCapitalMember 2018-10-01 2018-12-31 0001607549 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001607549 us-gaap:NoncontrollingInterestMember 2018-07-01 2018-09-30 0001607549 us-gaap:NoncontrollingInterestMember 2018-10-01 2018-12-31 0001607549 us-gaap:NoncontrollingInterestMember 2018-12-31 0001607549 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001607549 us-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0001607549 us-gaap:RetainedEarningsMember 2018-12-31 0001607549 2018-04-01 2018-06-30 0001607549 2018-07-01 2018-09-30 0001607549 2018-06-30 0001607549 2018-09-30 0001607549 2017-12-31 0001607549 us-gaap:CommonStockMember 2017-07-01 2017-09-30 0001607549 us-gaap:CommonStockMember 2017-10-01 2017-12-31 0001607549 appb:CommonStockToBeIssuedMember 2017-07-01 2017-09-30 0001607549 appb:CommonStockToBeIssuedMember 2017-10-01 2017-12-31 0001607549 us-gaap:AdditionalPaidInCapitalMember 2017-07-01 2017-09-30 0001607549 us-gaap:AdditionalPaidInCapitalMember 2017-10-01 2017-12-31 0001607549 us-gaap:NoncontrollingInterestMember 2017-07-01 2017-09-30 0001607549 us-gaap:NoncontrollingInterestMember 2017-10-01 2017-12-31 0001607549 us-gaap:RetainedEarningsMember 2017-07-01 2017-09-30 0001607549 us-gaap:RetainedEarningsMember 2017-10-01 2017-12-31 0001607549 2017-07-01 2017-09-30 0001607549 us-gaap:InvestorMember 2018-12-31 0001607549 us-gaap:SubsequentEventMember appb:JuulLabsIncMember 2019-02-28 0001607549 us-gaap:SubsequentEventMember 2019-01-01 0001607549 us-gaap:SubsequentEventMember 2019-02-01 2019-02-06 0001607549 us-gaap:SubsequentEventMember appb:JasonZitzerMember 2019-02-01 2019-02-06 0001607549 us-gaap:SubsequentEventMember appb:GordonFargasMember 2019-02-01 2019-02-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure APPLIED BIOSCIENCES CORP. 0001607549 10-Q 2018-12-31 false --03-31 Yes Non-accelerated Filer Q3 2019 13342113

0.00001

2.00

75000

695000

75000

1250000

100000

468537

873300

68237

250000

50000

100000

68537

654763

50000

100000

0.00001

5000000

200000000

263000 1656500

10499610

11597110

10499610

11597110

887

51000 51000 51000

28705

99900

28705

99900

1444500

1019500

Description of the Company   Applied BioSciences Corp. (formerly First Fixtures, Inc. and Stony Hill Corp. or the “Company”) was incorporated in the State of Nevada on February 21, 2014 and established a fiscal year end of March 31. Effective October 24, 2016 the Company changed its name from First Fixtures Inc. to Stony Hill Corp and on March 6, 2018, the Company changed its name from Stony Hill Corp. to Applied BioSciences Corp. The Company is focused on multiple areas of the hemp and CBD industry. Specifically, the Company is focused on select investments, branding, real estate, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.   Basis of presentation – Unaudited Financial Statements   The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the rules and regulations of the Securities and Exchange Commission. Accordingly, the unaudited condensed consolidated financial statements do not include all information and footnotes required by accounting principles generally accepted in the United States of America for complete annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of only normal recurring adjustments, considered necessary for a fair presentation. Interim operating results are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2019, or for any other interim period. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements as of and for the year ended March 31, 2018, which are included in the Company’s Report on Form 10-K for such year filed on June 28, 2018.   Going concern   These condensed statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. As reflected in the condensed consolidated financial statements, the Company incurred a net loss of $2,407,059 and used $788,863 of cash in operating activities during the nine months ended December 31, 2018. Further, the Company’s independent auditor in their audit report for fiscal year ended March 31, 2018 expressed substantial doubt about the Company’s ability to continue as a going concern. These and other factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.   The Company’s ability to continue as a going concern is dependent upon its ability to raise additional capital and to ultimately achieve sustainable revenues and income from operations. During the nine months ended December 31, 2018, the Company sold 37,500 shares of its common stock to accredited investors at a price of $2.00 per share for total proceeds of $75,000 and issued convertible notes for total proceeds of $1,444,500 both in private placements to accredited investors. However, the Company will need and is currently working on obtaining additional funds to operate its business through and beyond the date of this Form 10-Q filing. There is no assurance that such funds will be available or at terms acceptable to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions and covenants on its operations, in the case of debt financing or cause substantial dilution for its stockholders in the case of convertible debt and equity financing.

Equity investments relate to purchases of stock in certain entities with ownership percentages of less than 5%. As of March 31, 2018, these investments were recorded at their cost basis. On April 1, 2018, the Company adopted ASU 2016-01, Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities, and as such, these investments were recorded at their market value as of December 31, 2018. The investments consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom: black 1pt solid; text-align: center">December 31, 2018</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">March 31, 2018</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">(A) Cannabi-Tech Ltd. (Gemma)</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td id="ffcell" style="vertical-align: bottom; width: 9%; text-align: right">68,537</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">68,237</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">(B) Hightimes Holdings Corp.</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">654,763</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">250,000</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">(C) Precision Cultivation Systems, LLC</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">50,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">50,000</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">(D) Bailey Venture Partners XII LLC (JUUL)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">100,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">100,000</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">$</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">873,300</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">$</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">468,537</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>    (A) In November 2016, the Company purchased 29,571 shares of Preferred A stock of Cannabi-Tech Ltd. (“Cannabi”), at a price of $1.69086 per share for total investment of $50,000. In October 2017, the Company purchased 7,309 shares of Preferred A-1 stock of Cannabi at a price of $2.536 per share for total investment of $18,537. As of March 31, 2018, total investment amounted to $68,537, which accounts for less than 5% in Cannabi. Cannabi is a private company incorporated in the State of Israel that provides lab-grade medical cannabis quality control testing systems used to test the quality of medical marijuana flowers. The fair value of the investment at December 31, 2018 approximated its cost basis.   (B) In January 2017, the Company entered in to an agreement to purchase 59,524 shares of Class A common stock at a price of $4.20 per share for total investment of $250,000, which accounts for less than 5% investment in Hightimes Holdings Corp. (“Hightimes”). Hightimes owns Hight Times Magazine and hosts festivals, events and competitions including the High Times Cannabis Cup and multiple e-commerce properties, including HighTimes.com, CannabisCup.com and 420.com. As of September 30, 2018 and December 31, 2018, the Company was able to obtain observable evidence that the investment had a market value of $11.00 per share, or an aggregate value of $654,763. As such, the Company recorded an unrecognized gain from the change in market value of $404,763 during the nine months ended December 31, 2018.   (C) In June 2017, the Company entered in a Subscription Agreement to purchase 0.5% interest in Precision Cultivation Systems, LLC (“Precision”), a Delaware limited liability company, for a purchase price of $50,000. Precision is developing a growth system that capitalizes on a patent-pending cultivation method that utilizes proprietary irrigation and root zone conditioning. As part of the Subscription Agreement, $42,500 of the investment is subject to repayment on a pro-rata basis with other investors who have entered into similar Subscription Agreements. Amounts subject to repayment are solely at the discretion of Precision. The fair value of the investment at December 31, 2018 approximated its cost basis.   (D) In January 2018, the Company paid $100,000 for the purchase of a Membership Interest in Bailey Venture Partners XII LLC (“Bailey”) representing less than 5% interest in Bailey. Along with other funds received from third-party investors, Bailey plans to invest funds received in various strategic investments. The Company recorded this investment at cost and will recognize dividends, if any, when received, and will recognize gains or loss upon either selling the securities or recognize a loss prior to selling the securities if there is evidence that the fair market value of the investment has declined to below the recorded historical cost. The fair value of the investment at December 31, 2018 approximated its cost basis.    In February 2019, the Company received a distribution of approximately $186,000 from Bailey’s investment in JUUL Labs, Inc.     As the Company does not participate in the management of these companies nor has the ability to exercise significant influence over these companies, the Company recorded these investments at cost, and as of April 1, 2018, will adjust the cost basis to market at the end of each reporting period. Dividends, if any, will be recognized when received.   During the three months ended December 31, 2018, the Company paid $550,000 as a deposit towards the acquisition purchase price of Trace Analytics, Inc. (see Note 7), which was reflected as deposit on the acquisition in the accompanying condensed consolidated balance sheet as of the period then ended.

During the nine months ended December 31, 2018, the Company issued separate Convertible Promissory Notes (“Notes”) having a total principal amount of $1,444,500 to certain accredited holders. All outstanding principal together with interest on these Notes was due and payable on December 31, 2018 and accrued interest ranging from 1% to 8% per month, and 8% per annum. The note holders, at their sole discretion and election, were allowed to convert any part or all of the then outstanding principal and/or interest on these Notes into shares of common stock of the Company at a fixed price per share of $1.00. On December 31, 2018, all holders of the Notes converted the principal portion of their Notes to 1,444,500 shares of the Company’s common stock. The shares had not been issued as of December 31, 2018 and were reflected in “Common stock to be issued” in the condensed consolidated statement of stockholders’ equity during the period then ended.   A portion of the Notes with principal amount aggregating $1,019,500 were issued when the market price of the Company’s common stock was in excess of the $1.00 per share conversion price creating beneficial conversion feature associated with these Notes with an aggregate amount of $437,805 upon issuance dates. As such, the Company recorded $437,805 in additional paid-in capital and debt discount representing the intrinsic value of the beneficial conversion feature at the date of the borrowing against the Notes. The value of the beneficial conversion feature was fully amortized upon conversion of all of the outstanding Notes and reflected as interest expense for the nine months ended December 31, 2018.

In view of the Company’s limited operations and resources, none of the Company’s directors and/or officers received any compensation from the Company during the nine months ended December 31, 2018 and 2017.

Common Stock to be Issued   On February 23, 2017, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with mCig, Inc., a Nevada corporation (“mCig”) consisting of the issuance of an aggregate of 350,000 shares of common stock. Of the 350,000 shares of common stock consideration, 150,000 shares or $426,000 were not issued as of March 31, 2018 and were included in “Common stock to be issued” in the accompanying condensed consolidated statement of stockholders’ equity. During the nine months ended December 31, 2018, the Company issued 50,000 shares of common stock valued at $100,000 which was previously reflected as “Common stock to be issued” in the condensed consolidated statement of stockholders’ equity.   During the nine months ended December 31, 2018, the Company sold 37,500 shares of common stock, of which 25,000 shares had not been issued as of December 31, 2018 and is reflected in “Common stock to be issued” in the condensed consolidated statement of stockholders’ equity. The shares were sold at a price of $2.00 per share for total proceeds of $75,000 pursuant to a private placement Subscription Agreement with accredited investors. The Subscription Agreement offered up to one million shares of the Company’s common stock at a price per share of $2.00 per share. The Company made this offering solely to accredited investors, as defined under Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended.   Establishment of Advisory Board and Adoption of Charter   On April 28, 2017, the Company established an advisory board (the “Advisory Board”) and approved and adopted a charter (the “Advisory Board Charter”) to govern the Advisory Board. The Advisory Board shall be comprised of one or more directors (“Advisors”), and up to nine independent, non-Board, non-employee members, all of whom shall be appointed and subject to removal by the Board of Directors at any time.   During the nine months ended December 31, 2018, the Company appointed an advisor to the Advisory Board, which entitled him to an annual consulting fee 25,000 shares of the Company’s stock for a term of 6 months, with total fair value of $51,000.   Shares issued to consultants for services   During the nine months ended December 31, 2018, the Company granted an aggregate of 414,815 shares of its common stock to seven (7) consultants as payment for services rendered to the Company and recorded expense of $598,302 based on the fair value of the Company’s common stock at grant dates. Of the 414,815 shares granted, 29,815 shares valued at $61,852 had not been issued as of December 31, 2018 and were reflected in “Common stock to be issued” in the condensed consolidated statement of stockholders’ equity during the period then ended.     Shares issued to officers and directors for compensation   During the nine months ended December 31, 2018, the Company granted an aggregate of 625,000 shares of its common stock to one (1) board member and (2) officers of the Company as payment for services rendered to the Company and recorded expense of $756,250 based on the fair value of the Company’s common stock at grant dates.

Acquisition   On January 1, 2019, the Company entered into a Common Stock Purchase Agreement and closed on a purchase of 520,410 shares of common stock of Trace Analytics, Inc., a Washington corporation (“Trace Analytics”), at a purchase price of $2.40 per share, for an aggregate purchase price of $1,250,000, of which $750,000 was payable in cash and $500,000 of which will be paid in shares of common stock of the Company. During the three months ended December, 31, 2018, the Company paid $550,000 towards the acquisition purchase price of Trace Analytics, and which was reflected as deposit on the acquisition of Trace Analytics in the accompanying condensed consolidated balance sheet as of the period then ended. Immediately following the purchase, the Company holds 51% of the issued and outstanding shares of common stock of Trace Analytics. The Company is in the process of analizing the accounting effects of this transaction and historical financial statements of the acquired company and pro forma effects of the acquisition will be provided in a Form 8K/A to be subsequently filed.    On February 6, 2019, the Company issued an aggregate of 250,000 shares of common stock of the Company as payment for the shares of common stock payable to Trace Analytics. 125,000 of such shares were issued directly to Jason Zitzer, and 125,000 of such shares were issued directly to Gordon Fargas, both of whom are affiliates of Trace Analytics.    Trace Analytics is a cannabis testing laboratory and service company located in Spokane, Washington. Some of the services provided by Trace Analytics are:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr> <td style="width: 4%; text-align: justify"> </td> <td style="vertical-align: top; width: 4%; text-align: justify">·</td> <td style="vertical-align: top; text-align: justify">502 compulsory testing for all types of cannabis products;</td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: top; text-align: justify">·</td> <td style="vertical-align: top; text-align: justify">Industrial hemp CBD product testing;</td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: top; text-align: justify">·</td> <td style="vertical-align: top; text-align: justify">Extensive terpene, residual solvents, and cannabinoid profiles;</td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: top; text-align: justify">·</td> <td style="vertical-align: top; text-align: justify">Aflatoxin/Mycotoxin screening;</td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: top; text-align: justify">·</td> <td style="vertical-align: top; text-align: justify">Experienced grow consultation, evaluation and related services; and</td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: top; text-align: justify">·</td> <td style="vertical-align: top; text-align: justify">Edibles work up, process evaluation and dose distribution guidance.</td></tr> </table>    In connection with the Common Stock Purchase Agreement, the Company also entered into a Stockholders’ Agreement (the “Stockholders’ Agreement”), dated January 1, 2019, with Trace Analytics, Jason Zitzer, and Gordon Fargas. Mr. Zitzer and Mr. Fargas are affiliates of Trace Analytics and the only other stockholders of Trace Analytics, in addition to the Company. The Stockholders’ Agreement contains certain transfer restrictions and a right of first refusal which provides that if any party to the Stockholder’s Agreement proposes to transfer its Trace Analytics shares, Trace Analytics shall for a period of 30 days, have a first right of refusal to purchase such shares, followed by a first right of refusal for the remaining shareholders.   In connection with the Common Stock Purchase Agreement, the Company also entered into a Voting Agreement (the “Voting Agreement”), dated January 1, 2019, with Trace Analytics, Jason Zitzer, and Gordon Fargas. The Voting Agreement provides that the parties of the Voting Agreement shall vote their shares of common stock of Trace Analytics to appoint the three of the five members of the board of directors of Trace Analytics as designated by the Company, one member of the board of directors as designated by Mr. Ziter, and one member of the board of directors as designated by Mr. Fargas   Distribution   In February 2019, the Company received a distribution of approximately $186,000 from Bailey's investment in JUUL Labs, Inc.

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Applied Products LLC, VitaCBD LLC, an 80% owned entity, both Washington limited liability companies and SHL Management LLC, a Nevada limited liability company. Intercompany transactions and balances have been eliminated in consolidation. Management evaluates its investments on an individual basis for purposes of determining whether or not consolidation is appropriate.

Preparation of the condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Among other things, management estimates include the collectability of its accounts receivable, recoverability of inventory, assumptions made in determining impairment of investments and intangible assets, accruals for potential liabilities, and realization of deferred tax assets. These estimates generally involve complex issues and require judgments, involve analysis of historical information and the prediction of future trends, and are subject to change from period to period. Actual amounts could differ significantly from these estimates.

The Company adopted the guidance of ASC 606 on April 1, 2018, Revenue from Contracts with Customers (Topic 606), (ASC 606). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (1) identifying the contract(s) or agreement(s) with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied.    Under ASC 606, revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products or services to our customers based on written sales terms, which is also when control is transferred. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products or services to a customer.   The implementation of ASC 606 had no impact on the condensed consolidated financial statements and no cumulative effect adjustment was recognized.

The Company expenses advertising costs as incurred. Advertising expense for the three and nine months ended December 31, 2018 amounted to $100,730 and $556,167, respectively, and $165,315 and $229,674 for the three and nine months ended December 31, 2017 and are included in "Sales and Marketing expenses" in the Condensed Consolidated Statements of Operations.

The basic earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Shares of common stock to be issued are included in weighted average shares calculation from the date of grant. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the period. The diluted weighted average number of shares outstanding is the basic weighted average number of shares adjusted for any potentially dilutive debt or equity. Diluted earnings (loss) per share are the same as basic earnings (loss) per share due to the lack of dilutive items.

In February 2016, the FASB issued ASU No. 2016-02, Leases. This update will require the recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, for all leases with terms longer than 12 months. For operating leases, the asset and liability will be expensed over the lease term on a straight-line basis, with all cash flows included in the operating section of the statement of cash flows. For finance leases, interest on the lease liability will be recognized separately from the amortization of the right-of-use asset in the statement of comprehensive income and the repayment of the principal portion of the lease liability will be classified as a financing activity while the interest component will be included in the operating section of the statement of cash flows. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018. Early adoption is permitted. Upon adoption, leases will be recognized and measured at the beginning of the earliest period presented using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its financial statements and related disclosures.   In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” The ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The ASU also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Revenue from Contracts with Customers (Topic 606). The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. The Company is currently assessing the effect that the ASU will have on our financial position, results of operations, and disclosures.   Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom: black 1pt solid; text-align: center">December 31, 2018</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">March 31, 2018</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">(A) Cannabi-Tech Ltd. (Gemma)</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td id="ffcell" style="vertical-align: bottom; width: 9%; text-align: right">68,537</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">68,237</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">(B) Hightimes Holdings Corp.</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">654,763</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">250,000</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">(C) Precision Cultivation Systems, LLC</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">50,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">50,000</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">(D) Bailey Venture Partners XII LLC (JUUL)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">100,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">100,000</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">$</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">873,300</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">$</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">468,537</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table> Nevada 2014-02-21

37500

520410

50000

12500

347500

2.00

2.40

0.80

29571 59524 50000 7309 100000

1.69086

4.20

2.536

50000

18537

250000

ownership percentages of less than 5% accounts for less than 5% investment in High times Holdings Corp. representing less than 5% interest in Bailey. accounts for less than 5% in Cannabi. 0.005 42500 11.00

1444500

1.00

350000

705327

1808617

-9027

-18385

-2901933

-5299634

526000 1982352

3054297

4960791

105

116

35885

183377

14039

150246

21846

33131

705327

1808617

5500

4441

3563

226849

376254

124455

46756

29074

70105

12386

17822

0.08

25000

150000

29815

25000

678469

1643625

true true

426000 61852 414815 598302 P6M

Principles of Consolidation   The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Applied Products LLC, VitaCBD LLC, an 80% owned entity, both Washington limited liability companies and SHL Management LLC, a Nevada limited liability company. Intercompany transactions and balances have been eliminated in consolidation. Management evaluates its investments on an individual basis for purposes of determining whether or not consolidation is appropriate.   Use of Estimates and Assumptions   Preparation of the condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Among other things, management estimates include the collectability of its accounts receivable, recoverability of inventory, assumptions made in determining impairment of investments and intangible assets, accruals for potential liabilities, and realization of deferred tax assets. These estimates generally involve complex issues and require judgments, involve analysis of historical information and the prediction of future trends, and are subject to change from period to period. Actual amounts could differ significantly from these estimates.   Revenue Recognition   The Company adopted the guidance of ASC 606 on April 1, 2018, Revenue from Contracts with Customers (Topic 606), (ASC 606). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (1) identifying the contract(s) or agreement(s) with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied.    Under ASC 606, revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products or services to our customers based on written sales terms, which is also when control is transferred. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products or services to a customer.   The implementation of ASC 606 had no impact on the condensed consolidated financial statements and no cumulative effect adjustment was recognized.   Advertising   The Company expenses advertising costs as incurred. Advertising expense for the three and nine months ended December 31, 2018 amounted to $100,730 and $556,167, respectively, and $165,315 and $229,674 for the three and nine months ended December 31, 2017 and are included in "Sales and Marketing expenses" in the Condensed Consolidated Statements of Operations.    Earnings (Loss) per Share   The basic earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Shares of common stock to be issued are included in weighted average shares calculation from the date of grant. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the period. The diluted weighted average number of shares outstanding is the basic weighted average number of shares adjusted for any potentially dilutive debt or equity. Diluted earnings (loss) per share are the same as basic earnings (loss) per share due to the lack of dilutive items.   Investments   Through March 31, 2018, the Company used either the equity method or the cost method of accounting. The Company used the equity method for unconsolidated equity investments in which the Company was considered to have significant influence over the operations of the investee. The Company used the cost method for all other investments. Under the cost method, there is no change to the cost basis unless there is an other-than-temporary decline in value or dividends are received. If the decline is determined to be other-than-temporary, the Company writes down the cost basis of the investment to a new cost basis that represents realizable value.   On April 1, 2018, the Company adopted ASU 2016-01, Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 primarily affects equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. Among other things, this new guidance requires certain equity investments to be measured at fair value with changes in fair value recognized in net income. As such, the Company measures its equity investments at their fair value at end of each reporting period.   Investments accounted for under the equity method or cost method of accounting above are included in the caption "Equity investments" on the Condensed Consolidated Balance Sheets.   Recent Accounting Pronouncements   In February 2016, the FASB issued ASU No. 2016-02, Leases. This update will require the recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, for all leases with terms longer than 12 months. For operating leases, the asset and liability will be expensed over the lease term on a straight-line basis, with all cash flows included in the operating section of the statement of cash flows. For finance leases, interest on the lease liability will be recognized separately from the amortization of the right-of-use asset in the statement of comprehensive income and the repayment of the principal portion of the lease liability will be classified as a financing activity while the interest component will be included in the operating section of the statement of cash flows. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018. Early adoption is permitted. Upon adoption, leases will be recognized and measured at the beginning of the earliest period presented using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its financial statements and related disclosures.   In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” The ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The ASU also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Revenue from Contracts with Customers (Topic 606). The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. The Company is currently assessing the effect that the ASU will have on our financial position, results of operations, and disclosures.   Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

Through March 31, 2018, the Company used either the equity method or the cost method of accounting. The Company used the equity method for unconsolidated equity investments in which the Company was considered to have significant influence over the operations of the investee. The Company used the cost method for all other investments. Under the cost method, there is no change to the cost basis unless there is an other-than-temporary decline in value or dividends are received. If the decline is determined to be other-than-temporary, the Company writes down the cost basis of the investment to a new cost basis that represents realizable value.   On April 1, 2018, the Company adopted ASU 2016-01, Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 primarily affects equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. Among other things, this new guidance requires certain equity investments to be measured at fair value with changes in fair value recognized in net income. As such, the Company measures its equity investments at their fair value at end of each reporting period.   Investments accounted for under the equity method or cost method of accounting above are included in the caption "Equity investments" on the Condensed Consolidated Balance Sheets.

60934

241571

212637

416831

669442

1625240

152

426000

1742472

1736

-525832

152

476000

1742472

2932

-724232

154

476000

2437470

2875

-901582

154

538333

2437470

-4261

-1237302

105

526000

3054297

-9027

-2901933

107

546926

3414000

-15283

-3297434

1644528

1497324

2014917

107

537852

3538900

-18619

-3407857

116

1982352

4960791

-18385

-5299634

648316

650383

1734394

550000

32769

38828

12607

33527

439740

140706

50370

379582

472509

179534

62977

413109

2269711

756295

355464

1418491

877

168428

56172

292

1712667

358193

133977

1317469

556167

229674

165315

100730

-2236942

-717467

-342857

-1384964

-2407059

1196

-198400

-197204

-6256

-395501

-717467

-342856

-1891543

-3336

234

-110423

-1891777

-401757

-113759

-57

-7136

-177350

-335720

-177407

-170117

-506579

574880

506579

404763

-2397701

-711470

-335726

-1891777

-9358

-5997

-7131

234

-0.22

-0.05

-0.02

-0.16

11150168

15458775

15595100

11797297

649302 112333

168384

878

-788863

-420701

147492

20188

-5500

77699

12630

-41031

-12305

-5436

992

437805

756250

550000

1568

-550000

-70105

1519500

695000

180637

204194

1444500 437805

15247600

15595100

10499610

10664610

10677110

11597110

75000

-25000

25000

75000

694998

695000

50000 50000 62333 62333 50000 1 -100000 99999 90000 295000 1 45926 179999 356450 3 15926 356447 225926 15926 25000 625000 625000 756250 756250 6 756244 309200 309200

1444500

186000

2018-12-31

accrued interest ranging from 1% to 8% per month, and 8% per annum. 1444500 On January 1, 2019, the Company entered into a Common Stock Purchase Agreement and closed on a purchase of 520,410 shares of common stock of Trace Analytics, Inc., a Washington corporation (“Trace Analytics”), at a purchase price of $2.40 per share, for an aggregate purchase price of $1,250,000, of which $750,000 was payable in cash and $500,000 of which will be paid in shares of common stock of the Company. During the three months ended December, 31, 2018, the Company paid $550,000 towards the acquisition purchase price of Trace Analytics, and which was reflected as deposit on the acquisition of Trace Analytics in the accompanying condensed consolidated balance sheet as of the period then ended. false

-68537

250000

125000

EX-101.SCH 7 appb-20181231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - INVESTMENT link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - CONVERTIBLE NOTE link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - EQUITY link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - INVESTMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - INVESTMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - CONVERTIBLE NOTE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 appb-20181231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 appb-20181231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 appb-20181231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Series A preferred stock [Member] Equity Components [Axis] Common Stock $0.00001 Par Common StockTo Be Issued Additional Paid-In Capital Non-Controlling Interest Accumulated Deficit Common stock A [Member] Cannabi-Tech Ltd [Member] Hightimes Holdings Corp [Member] Common Stock to be Issued Precision Cultivation Systems, LLC [Member] Title of Individual [Axis] mCig LLC [Member] Bailey Venture Partners XII LLC [Member] Cannabi-Tech Ltd. [Member] Plan Name [Axis] Applied Products LLC [Member] VitaCBD LLC [Member] Debt Instrument [Axis] Convertible Promissory Notes [Member] Related Party [Axis] Investor [Member] Consulting Agreement [Member] Seven Consultants [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Asset Purchase Agreement [Member] Advisory Board [Member] Common Stock Non - Controlling Interest Business Acquisition [Axis] JUUL Labs, Inc [Member] Jason Zitzer [Member] Gordon Fargas [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity's Reporting Status Current? Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Entity Emerging Growth Company Entity Small Business Entity Ex Transition Period Statement of Financial Position [Abstract] ASSETS Current Assets Cash Accounts receivable, net of allowance of nil and $887 at December 31, 2018 (unaudited) and March 31, 2018, respectively Inventory Prepaids and other current assets Total Current Assets Property and equipment, net Equity investments Deposit on the acquisition of Trace Analytics, Inc. Other asset TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable Accrued expenses Total Current Liabilities Stockholders' Equity Preferred stock; $0.00001 par value; 5,000,000 shares authorized; none issued and outstanding at December 31, 2018 (unaudited) and March 31, 2018 Common stock; $0.00001 par value; 200,000,000 shares authorized; 11,597,110 and 10,499,610 issued and outstanding at December 31, 2018 (unaudited) and March 31, 2018, respectively Additional paid in capital Common stock to be issued, 1,656,500 and 263,000 shares at December 31, 2018 (unaudited) and March 31, 2018, respectively Accumulated deficit Total Applied BioSciences Corp. Stockholders' Equity Non-controlling interest Total Stockholders' Equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Accounts receivable, net of allowance Preferred stock, par value Preferred stock, authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value Common stock, authorized Common stock, issued Common stock, outstanding Common stock shares to be issued Condensed Consolidated Statements Of Operations PRODUCT REVENUE, NET COST OF REVENUE, PRODUCT GROSS MARGIN EXPENSES Sales and marketing (including stock based compensation of nil, $47,111, $210,000 and $47,111, respectively) General and administrative (including stock based compensation of $1,133,534, $13,889, $1,271,959 and $26,389, respectively) Depreciation and Amortization TOTAL OPERATING EXPENSES OPERATING LOSS Other Income (Expense) Unrealized gain on equity investments Interest Expense Total other income, net NET LOSS Less: Net loss (income) attributable to non controlling interest NET LOSS ATTRIBUTABLE TO APPLIED BIOSCIENCES CORP. LOSS PER COMMON SHARE WEIGHTED AVERAGE SHARES OUTSTANDING Basic and diluted Statement [Table] Statement [Line Items] Beginning Balance, Shares Beginning Balance, Amount Common stock to be issued in conjunction with consulting agreement Issuance of common stock for cash, Shares Issuance of common stock for cash, Amount Issuance of common stock previously committed but not issued, Shares Issuance of common stock previously committed but not issued, Amount Fair value of shares issued to consultant for services, Shares Fair value of shares issued to consultant for services, Amount Fair value of shares issued to advisory board member, Shares Fair value of shares issued to advisory board member, Amount Beneficial conversion feature associated with issuance of convertible notes Fair value of shares issued to Company Officers and board member, Shares Fair value of shares issued to Company Officers and board member, Amount Beneficial conversion feature associated with a convertible note Conversion of convertible debt Net income (loss) Ending Balance, Shares Ending Balance, Amount Condensed Consolidated Statements Of Cash Flows CASH FLOWS FROM OPERATING ACTIVITIES Net loss Adjustment to reconcile net loss to net cash used in operating activities: Unrealized gain on equity investments Amortization of debt discount Fair value of shares issued to consultants Fair value of shares issued to officers and board member Depreciation Amortization of intangible Changes in operating assets and liabilities Accounts receivable Inventory Prepaid and other current assets Other asset Accounts payable and accrued expenses Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Deposit on acquisition Acquisition of equity investments Purchase of property and equipment Net cash used in investing activities CASH FLOW FROM FINANCING ACTIVITIES Proceeds from issuance of convertible notes Proceeds from issuance of common stock Net cash provided by financing activities NET CHANGE IN CASH CASH, BEGINNING OF PERIOD CASH, END OF PERIOD NON-CASH INVESTING AND FINANCING ACTIVITIES Fair value of common stock issued upon conversion of convertible notes Fair value of beneficial conversion feature related to issuance of convertible notes Notes to Financial Statements NOTE 1 - NATURE OF OPERATIONS AND BASIS OF PRESENTATION NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES NOTE 3 - INVESTMENT NOTE 4 - CONVERTIBLE NOTE NOTE 5 - RELATED PARTY TRANSACTIONS NOTE 6 - EQUITY NOTE 7 - SUBSEQUENT EVENTS Summary Of Significant Accounting Policies Principles of Consolidation Use of Estimates and Assumptions Revenue Recognition Advertising Earnings (Loss) per Share Investments Recent Accounting Pronouncements Investments Stock equity investments State of incorporation Date of incorporation Net cash used in operating activities Issuance of common stock for cash, Share Issuance of common stock for cash Common stock, price per share Issuance of convertible note Owned Interest entity Advertising expense Purchase of stock Stock price per share Total investment Ownership percentages description Interest rate Repayment of investment, pro-rata basis Market value per share Cash distributions Principal amount Convertible debt maturity date EX-101.PRE 11 appb-20181231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Dec. 31, 2018	Feb. 08, 2019
Document And Entity Information
Entity Registrant Name	APPLIED BIOSCIENCES CORP.
Entity Central Index Key	0001607549
Document Type	10-Q
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		13,342,113
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Ex Transition Period	false

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2018	Mar. 31, 2018
Current Assets
Cash	$ 241,571	$ 60,934
Accounts receivable, net of allowance of nil and $887 at December 31, 2018 (unaudited) and March 31, 2018, respectively	17,822	12,386
Inventory	70,105	29,074
Prepaids and other current assets	46,756	124,455
Total Current Assets	376,254	226,849
Property and equipment, net	3,563	4,441
Equity investments	873,300	468,537
Deposit on the acquisition of Trace Analytics, Inc.	550,000
Other asset	5,500	5,500
TOTAL ASSETS	1,808,617	705,327
Current Liabilities
Accounts payable	33,131	21,846
Accrued expenses	150,246	14,039
Total Current Liabilities	183,377	35,885
Stockholders' Equity
Preferred stock; $0.00001 par value; 5,000,000 shares authorized; none issued and outstanding at December 31, 2018 (unaudited) and March 31, 2018
Common stock; $0.00001 par value; 200,000,000 shares authorized; 11,597,110 and 10,499,610 issued and outstanding at December 31, 2018 (unaudited) and March 31, 2018, respectively	116	105
Additional paid in capital	4,960,791	3,054,297
Common stock to be issued, 1,656,500 and 263,000 shares at December 31, 2018 (unaudited) and March 31, 2018, respectively	1,982,352	526,000
Accumulated deficit	(5,299,634)	(2,901,933)
Total Applied BioSciences Corp. Stockholders' Equity	1,643,625	678,469
Non-controlling interest	(18,385)	(9,027)
Total Stockholders' Equity	1,625,240	669,442
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 1,808,617	$ 705,327

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Dec. 31, 2018	Mar. 31, 2018
Current Assets
Accounts receivable, net of allowance		$ 887
Stockholders' Equity
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, authorized	200,000,000	200,000,000
Common stock, issued	11,597,110	10,499,610
Common stock, outstanding	11,597,110	10,499,610
Common stock shares to be issued	1,656,500	263,000

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Condensed Consolidated Statements Of Operations
PRODUCT REVENUE, NET	$ 413,109	$ 62,977	$ 472,509	$ 179,534
COST OF REVENUE, PRODUCT	379,582	50,370	439,740	140,706
GROSS MARGIN	33,527	12,607	32,769	38,828
EXPENSES
Sales and marketing (including stock based compensation of nil, $47,111, $210,000 and $47,111, respectively)	100,730	165,315	556,167	229,674
General and administrative (including stock based compensation of $1,133,534, $13,889, $1,271,959 and $26,389, respectively)	1,317,469	133,977	1,712,667	358,193
Depreciation and Amortization	292	56,172	877	168,428
TOTAL OPERATING EXPENSES	1,418,491	355,464	2,269,711	756,295
OPERATING LOSS	(1,384,964)	(342,857)	(2,236,942)	(717,467)
Other Income (Expense)
Unrealized gain on equity investments			404,763
Interest Expense	(506,579)		(574,880)
Total other income, net	(506,579)		(170,117)
NET LOSS	(1,891,543)	(342,856)	(2,407,059)	(717,467)
Less: Net loss (income) attributable to non controlling interest	(234)	7,131	9,358	5,997
NET LOSS ATTRIBUTABLE TO APPLIED BIOSCIENCES CORP.	$ (1,891,777)	$ (335,726)	$ (2,397,701)	$ (711,470)
LOSS PER COMMON SHARE	$ (0.16)	$ (0.02)	$ (0.22)	$ (0.05)
WEIGHTED AVERAGE SHARES OUTSTANDING
Basic and diluted	11,797,297	15,595,100	11,150,168	15,458,775

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY (Unaudited) - USD ($)	Common Stock $0.00001 Par	Common Stock to be Issued	Additional Paid-In Capital	Non-Controlling Interest	Accumulated Deficit	Total
Beginning Balance, Shares at Mar. 31, 2017	15,247,600
Beginning Balance, Amount at Mar. 31, 2017	$ 152	$ 426,000	$ 1,742,472	$ 1,736	$ (525,832)	$ 1,644,528
Common stock to be issued in conjunction with consulting agreement		50,000				50,000
Net income (loss)				1,196	(198,400)	(197,204)
Ending Balance, Shares at Jun. 30, 2017	15,247,600
Ending Balance, Amount at Jun. 30, 2017	$ 152	476,000	1,742,472	2,932	(724,232)	1,497,324
Beginning Balance, Shares at Mar. 31, 2017	15,247,600
Beginning Balance, Amount at Mar. 31, 2017	$ 152	426,000	1,742,472	1,736	(525,832)	1,644,528
Net income (loss)						(717,467)
Ending Balance, Shares at Dec. 31, 2017	15,595,100
Ending Balance, Amount at Dec. 31, 2017	$ 154	538,333	2,437,470	(4,261)	(1,237,302)	1,734,394
Beginning Balance, Shares at Jun. 30, 2017	15,247,600
Beginning Balance, Amount at Jun. 30, 2017	$ 152	476,000	1,742,472	2,932	(724,232)	1,497,324
Issuance of common stock for cash, Shares	347,500
Issuance of common stock for cash, Amount	$ 2		694,998			695,000
Net income (loss)				(57)	(177,350)	(177,407)
Ending Balance, Shares at Sep. 30, 2017	15,595,100
Ending Balance, Amount at Sep. 30, 2017	$ 154	476,000	2,437,470	2,875	(901,582)	2,014,917
Common stock to be issued in conjunction with consulting agreement		62,333				62,333
Net income (loss)				(7,136)	(335,720)	(342,856)
Ending Balance, Shares at Dec. 31, 2017	15,595,100
Ending Balance, Amount at Dec. 31, 2017	$ 154	538,333	2,437,470	(4,261)	(1,237,302)	1,734,394
Beginning Balance, Shares at Mar. 31, 2018	10,499,610
Beginning Balance, Amount at Mar. 31, 2018	$ 105	526,000	3,054,297	(9,027)	(2,901,933)	669,442
Issuance of common stock for cash, Shares
Issuance of common stock for cash, Amount		75,000				75,000
Issuance of common stock previously committed but not issued, Shares	50,000
Issuance of common stock previously committed but not issued, Amount	$ 1	(100,000)	99,999
Fair value of shares issued to consultant for services, Shares	90,000
Fair value of shares issued to consultant for services, Amount	$ 1	45,926	179,999			225,926
Fair value of shares issued to advisory board member, Shares	25,000
Fair value of shares issued to advisory board member, Amount			51,000			51,000
Beneficial conversion feature associated with issuance of convertible notes			28,705			28,705
Net income (loss)				(6,256)	(395,501)	(401,757)
Ending Balance, Shares at Jun. 30, 2018	10,664,610
Ending Balance, Amount at Jun. 30, 2018	$ 107	546,926	3,414,000	(15,283)	(3,297,434)	648,316
Beginning Balance, Shares at Mar. 31, 2018	10,499,610
Beginning Balance, Amount at Mar. 31, 2018	$ 105	526,000	3,054,297	(9,027)	(2,901,933)	$ 669,442
Fair value of shares issued to Company Officers and board member, Shares						625,000
Fair value of shares issued to Company Officers and board member, Amount						$ 756,250
Net income (loss)						(2,407,059)
Ending Balance, Shares at Dec. 31, 2018	11,597,110
Ending Balance, Amount at Dec. 31, 2018	$ 116	1,982,352	4,960,791	(18,385)	(5,299,634)	1,625,240
Beginning Balance, Shares at Jun. 30, 2018	10,664,610
Beginning Balance, Amount at Jun. 30, 2018	$ 107	546,926	3,414,000	(15,283)	(3,297,434)	648,316
Issuance of common stock for cash, Shares	12,500
Issuance of common stock for cash, Amount		(25,000)	25,000
Fair value of shares issued to consultant for services, Shares
Fair value of shares issued to consultant for services, Amount		15,926				15,926
Beneficial conversion feature associated with issuance of convertible notes			99,900			99,900
Net income (loss)				(3,336)	(110,423)	(113,759)
Ending Balance, Shares at Sep. 30, 2018	10,677,110
Ending Balance, Amount at Sep. 30, 2018	$ 107	537,852	3,538,900	(18,619)	(3,407,857)	650,383
Fair value of shares issued to consultant for services, Shares	295,000
Fair value of shares issued to consultant for services, Amount	$ 3		356,447			356,450
Fair value of shares issued to Company Officers and board member, Shares	625,000
Fair value of shares issued to Company Officers and board member, Amount	$ 6		756,244			756,250
Beneficial conversion feature associated with a convertible note			309,200			309,200
Conversion of convertible debt		1,444,500				1,444,500
Net income (loss)				234	(1,891,777)	(1,891,543)
Ending Balance, Shares at Dec. 31, 2018	11,597,110
Ending Balance, Amount at Dec. 31, 2018	$ 116	$ 1,982,352	$ 4,960,791	$ (18,385)	$ (5,299,634)	$ 1,625,240

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (2,407,059)	$ (717,467)
Adjustment to reconcile net loss to net cash used in operating activities:
Unrealized gain on equity investments	(404,763)
Amortization of debt discount	437,805
Fair value of shares issued to consultants	649,302	112,333
Fair value of shares issued to officers and board member	756,250
Depreciation	878	44
Amortization of intangible		168,384
Changes in operating assets and liabilities
Accounts receivable	(5,436)	992
Inventory	(41,031)	(12,305)
Prepaid and other current assets	77,699	12,630
Other asset		(5,500)
Accounts payable and accrued expenses	147,492	20,188
Net cash used in operating activities	(788,863)	(420,701)
CASH FLOWS FROM INVESTING ACTIVITIES
Deposit on acquisition	(550,000)
Acquisition of equity investments		(68,537)
Purchase of property and equipment		(1,568)
Net cash used in investing activities	(550,000)	(70,105)
CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from issuance of convertible notes	1,444,500
Proceeds from issuance of common stock	75,000	695,000
Net cash provided by financing activities	1,519,500	695,000
NET CHANGE IN CASH	180,637	204,194
CASH, BEGINNING OF PERIOD	60,934	212,637
CASH, END OF PERIOD	241,571	416,831
NON-CASH INVESTING AND FINANCING ACTIVITIES
Fair value of common stock issued upon conversion of convertible notes	1,444,500
Fair value of beneficial conversion feature related to issuance of convertible notes	$ 437,805

XML 18 R7.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS AND BASIS OF PRESENTATION

9 Months Ended

Dec. 31, 2018

Notes to Financial Statements

NOTE 1 - NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Description of the Company

Basis of presentation – Unaudited Financial Statements

Going concern

XML 19 R8.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Dec. 31, 2018

Notes to Financial Statements

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

Use of Estimates and Assumptions

Revenue Recognition

The implementation of ASC 606 had no impact on the condensed consolidated financial statements and no cumulative effect adjustment was recognized.

Advertising

Earnings (Loss) per Share

Investments

Investments accounted for under the equity method or cost method of accounting above are included in the caption "Equity investments" on the Condensed Consolidated Balance Sheets.

Recent Accounting Pronouncements

XML 20 R9.htm IDEA: XBRL DOCUMENT

INVESTMENT

9 Months Ended

Dec. 31, 2018

Notes to Financial Statements

NOTE 3 - INVESTMENT

	December 31, 2018		March 31, 2018
(A) Cannabi-Tech Ltd. (Gemma)	$	68,537	$	68,237
(B) Hightimes Holdings Corp.		654,763		250,000
(C) Precision Cultivation Systems, LLC		50,000		50,000
(D) Bailey Venture Partners XII LLC (JUUL)		100,000		100,000
	$	873,300	$	468,537

In February 2019, the Company received a distribution of approximately $186,000 from Bailey’s investment in JUUL Labs, Inc.

XML 21 R10.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTE

9 Months Ended

Dec. 31, 2018

Notes to Financial Statements

NOTE 4 - CONVERTIBLE NOTE

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

XML 22 R11.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS	9 Months Ended
RELATED PARTY TRANSACTIONS	Dec. 31, 2018
Notes to Financial Statements
NOTE 5 - RELATED PARTY TRANSACTIONS	In view of the Company’s limited operations and resources, none of the Company’s directors and/or officers received any compensation from the Company during the nine months ended December 31, 2018 and 2017.

XML 23 R12.htm IDEA: XBRL DOCUMENT

EQUITY

9 Months Ended

Dec. 31, 2018

Notes to Financial Statements

NOTE 6 - EQUITY

Common Stock to be Issued

Establishment of Advisory Board and Adoption of Charter

Shares issued to consultants for services

Shares issued to officers and directors for compensation

XML 24 R13.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

9 Months Ended

Dec. 31, 2018

Notes to Financial Statements

NOTE 7 - SUBSEQUENT EVENTS

Acquisition

Trace Analytics is a cannabis testing laboratory and service company located in Spokane, Washington. Some of the services provided by Trace Analytics are:

	·	502 compulsory testing for all types of cannabis products;
	·	Industrial hemp CBD product testing;
	·	Extensive terpene, residual solvents, and cannabinoid profiles;
	·	Aflatoxin/Mycotoxin screening;
	·	Experienced grow consultation, evaluation and related services; and
	·	Edibles work up, process evaluation and dose distribution guidance.

Distribution

In February 2019, the Company received a distribution of approximately $186,000 from Bailey's investment in JUUL Labs, Inc.

XML 25 R14.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Dec. 31, 2018
Summary Of Significant Accounting Policies
Principles of Consolidation	The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Applied Products LLC, VitaCBD LLC, an 80% owned entity, both Washington limited liability companies and SHL Management LLC, a Nevada limited liability company. Intercompany transactions and balances have been eliminated in consolidation. Management evaluates its investments on an individual basis for purposes of determining whether or not consolidation is appropriate.
Use of Estimates and Assumptions	Preparation of the condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Among other things, management estimates include the collectability of its accounts receivable, recoverability of inventory, assumptions made in determining impairment of investments and intangible assets, accruals for potential liabilities, and realization of deferred tax assets. These estimates generally involve complex issues and require judgments, involve analysis of historical information and the prediction of future trends, and are subject to change from period to period. Actual amounts could differ significantly from these estimates.
Revenue Recognition	The Company adopted the guidance of ASC 606 on April 1, 2018, Revenue from Contracts with Customers (Topic 606), (ASC 606). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (1) identifying the contract(s) or agreement(s) with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. Under ASC 606, revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products or services to our customers based on written sales terms, which is also when control is transferred. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products or services to a customer. The implementation of ASC 606 had no impact on the condensed consolidated financial statements and no cumulative effect adjustment was recognized.
Advertising	The Company expenses advertising costs as incurred. Advertising expense for the three and nine months ended December 31, 2018 amounted to $100,730 and $556,167, respectively, and $165,315 and $229,674 for the three and nine months ended December 31, 2017 and are included in "Sales and Marketing expenses" in the Condensed Consolidated Statements of Operations.
Earnings (Loss) per Share	The basic earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Shares of common stock to be issued are included in weighted average shares calculation from the date of grant. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the period. The diluted weighted average number of shares outstanding is the basic weighted average number of shares adjusted for any potentially dilutive debt or equity. Diluted earnings (loss) per share are the same as basic earnings (loss) per share due to the lack of dilutive items.
Investments	Through March 31, 2018, the Company used either the equity method or the cost method of accounting. The Company used the equity method for unconsolidated equity investments in which the Company was considered to have significant influence over the operations of the investee. The Company used the cost method for all other investments. Under the cost method, there is no change to the cost basis unless there is an other-than-temporary decline in value or dividends are received. If the decline is determined to be other-than-temporary, the Company writes down the cost basis of the investment to a new cost basis that represents realizable value. On April 1, 2018, the Company adopted ASU 2016-01, Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 primarily affects equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. Among other things, this new guidance requires certain equity investments to be measured at fair value with changes in fair value recognized in net income. As such, the Company measures its equity investments at their fair value at end of each reporting period. Investments accounted for under the equity method or cost method of accounting above are included in the caption "Equity investments" on the Condensed Consolidated Balance Sheets.
Recent Accounting Pronouncements	In February 2016, the FASB issued ASU No. 2016-02, Leases. This update will require the recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, for all leases with terms longer than 12 months. For operating leases, the asset and liability will be expensed over the lease term on a straight-line basis, with all cash flows included in the operating section of the statement of cash flows. For finance leases, interest on the lease liability will be recognized separately from the amortization of the right-of-use asset in the statement of comprehensive income and the repayment of the principal portion of the lease liability will be classified as a financing activity while the interest component will be included in the operating section of the statement of cash flows. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018. Early adoption is permitted. Upon adoption, leases will be recognized and measured at the beginning of the earliest period presented using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its financial statements and related disclosures. In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” The ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The ASU also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Revenue from Contracts with Customers (Topic 606). The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. The Company is currently assessing the effect that the ASU will have on our financial position, results of operations, and disclosures. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

- Definition

Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.

+ References + Details

XML 26 R15.htm IDEA: XBRL DOCUMENT

INVESTMENTS (Tables)

9 Months Ended

Dec. 31, 2018

Investments Tables Abstract

Stock equity investments

	December 31, 2018		March 31, 2018
(A) Cannabi-Tech Ltd. (Gemma)	$	68,537	$	68,237
(B) Hightimes Holdings Corp.		654,763		250,000
(C) Precision Cultivation Systems, LLC		50,000		50,000
(D) Bailey Venture Partners XII LLC (JUUL)		100,000		100,000
	$	873,300	$	468,537

XML 27 R16.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Dec. 31, 2018	Dec. 31, 2017
State of incorporation							Nevada
Date of incorporation							Feb. 21, 2014
Net loss	$ (1,891,543)	$ (113,759)	$ (401,757)	$ (342,856)	$ (177,407)	$ (197,204)	$ (2,407,059)	$ (717,467)
Net cash used in operating activities							(788,863)	(420,701)
Issuance of common stock for cash							$ 75,000	695,000
Common stock, price per share	$ 2.00						$ 2.00
Issuance of convertible note							$ 1,444,500
Investor [Member]
Issuance of common stock for cash, Share							37,500
Issuance of common stock for cash							$ 75,000
Common stock, price per share	$ 2.00						$ 2.00

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 28 R17.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Advertising expense	$ 100,730	$ 165,315	$ 556,167	$ 229,674
Applied Products LLC [Member] \| VitaCBD LLC [Member]
Owned Interest entity			80.00%

XML 29 R18.htm IDEA: XBRL DOCUMENT

INVESTMENTS (Details) - USD ($)	Dec. 31, 2018	Mar. 31, 2018
Equity investments	$ 873,300	$ 468,537
Cannabi-Tech Ltd [Member]
Equity investments	68,537	68,237
Hightimes Holdings Corp [Member]
Equity investments	654,763	250,000
Precision Cultivation Systems, LLC [Member]
Equity investments	50,000	50,000
Bailey Venture Partners XII LLC [Member]
Equity investments	$ 100,000	$ 100,000

XML 30 R19.htm IDEA: XBRL DOCUMENT

INVESTMENTS (Details Narrative) - USD ($)	1 Months Ended						3 Months Ended		9 Months Ended
INVESTMENTS (Details Narrative) - USD ($)	Mar. 31, 2018	Jan. 31, 2018	Oct. 31, 2017	Jun. 30, 2017	Jan. 31, 2017	Nov. 30, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Feb. 28, 2019
Equity investments	$ 468,537						$ 873,300		$ 873,300
Ownership percentages description									ownership percentages of less than 5%
Unrealized gain on equity investments									$ 404,763
Deposit on acquisition									(550,000)
Series A preferred stock [Member]
Purchase of stock			7,309			29,571
Stock price per share			$ 2.536			$ 1.69086
Total investment			$ 18,537			$ 50,000
Common stock A [Member]
Purchase of stock					59,524
Stock price per share					$ 4.20
Total investment					$ 250,000
Ownership percentages description					accounts for less than 5% investment in High times Holdings Corp.
Precision Cultivation Systems, LLC [Member]
Purchase of stock				50,000
Interest rate				0.50%
Repayment of investment, pro-rata basis				$ 42,500
Bailey Venture Partners XII LLC [Member]
Purchase of stock		100,000
Ownership percentages description		representing less than 5% interest in Bailey.
Cannabi-Tech Ltd. [Member]
Equity investments	$ 68,537
Ownership percentages description	accounts for less than 5% in Cannabi.
Hightimes Holdings Corp [Member]
Equity investments	$ 250,000						$ 654,763		$ 654,763
Market value per share							$ 11.00		$ 11.00
Subsequent Event [Member] \| JUUL Labs, Inc [Member]
Cash distributions											$ 186,000

XML 31 R20.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTE (Details Narrative) - USD ($)	9 Months Ended
CONVERTIBLE NOTE (Details Narrative) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Issuance of convertible note	$ 1,444,500
Amortization of debt discount	437,805
Fair value of beneficial conversion feature related to issuance of convertible notes	437,805
Convertible Promissory Notes [Member]
Principal amount	$ 1,444,500
Convertible debt maturity date	Dec. 31, 2018
Interest rate	8.00%
Interest rate description	accrued interest ranging from 1% to 8% per month, and 8% per annum.
Issuance of convertible note	$ 1,019,500
Fixed price per share	$ 1.00
Conversion price	$ 1.00
Conversion of convertible debt, Shares	1,444,500

XML 32 R21.htm IDEA: XBRL DOCUMENT

EQUITY (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
EQUITY (Details Narrative) - USD ($)	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Mar. 31, 2018	Feb. 23, 2017
Fair value of shares issued to advisory board member, Amount		$ 51,000
Issuance of common stock for cash			$ 75,000	$ 695,000
Sale of common stock, price per share	$ 2.00		$ 2.00
Common stock, per share	$ 0.00001		$ 0.00001		$ 0.00001
Fair value of shares issued to Company Officers and board member, Shares			625,000
Fair value of shares issued to Company Officers and board member, Amount	$ 756,250		$ 756,250
Investor [Member]
Issuance of common stock for cash, shares			37,500
Issuance of common stock for cash			$ 75,000
Sale of common stock, price per share	$ 2.00		$ 2.00
Common stock, per share	$ 2.00		$ 2.00
Common stock, shares unissued, shares	25,000		25,000
Asset Purchase Agreement [Member]
Issuance of common stock for cash, shares			50,000
Issuance of common stock for cash			$ 100,000
Advisory Board [Member]
Fair value of shares issued to advisory board member, Shares			25,000
Fair value of shares issued to advisory board member, Amount			$ 51,000
Consulting agreement term			6 months
mCig LLC [Member]
Aggregate common stock shares issued						350,000
Common stock, shares unissued, shares						150,000
Common stock, shares unissued, value						$ 426,000
Seven Consultants [Member] \| Consulting Agreement [Member]
Common stock, shares unissued, shares	29,815		29,815
Common stock, shares unissued, value	$ 61,852		$ 61,852
Common stock shares granted	414,815		414,815
Expense related to shares granted	$ 598,302		$ 598,302

XML 33 R22.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative) - USD ($)			9 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Feb. 06, 2019	Jan. 01, 2019	Dec. 31, 2018	Dec. 31, 2017	Feb. 28, 2019
Issuance of common stock for cash			$ 75,000	$ 695,000
Sale of common stock, price per share			$ 2.00
Subsequent Event [Member]
Common stock purchase agreement, description		<p style="margin: 0pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On January 1, 2019, the Company entered into a Common Stock Purchase Agreement and closed on a purchase of 520,410 shares of common stock of Trace Analytics, Inc., a Washington corporation (“Trace Analytics”), at a purchase price of $2.40 per share, for an aggregate purchase price of $1,250,000, of which $750,000 was payable in cash and $500,000 of which will be paid in shares of common stock of the Company. During the three months ended December, 31, 2018, the Company paid $550,000 towards the acquisition purchase price of Trace Analytics, and which was reflected as deposit on the acquisition of Trace Analytics in the accompanying condensed consolidated balance sheet as of the period then ended.</font></p>
Issuance of common stock for cash, shares		520,410
Issuance of common stock for cash		$ 1,250,000
Sale of common stock, price per share		$ 2.40
Common stock issued for services, shares	250,000
Subsequent Event [Member] \| Jason Zitzer [Member]
Common stock issued for services, shares	125,000
Subsequent Event [Member] \| Gordon Fargas [Member]
Common stock issued for services, shares	125,000
Subsequent Event [Member] \| JUUL Labs, Inc [Member]
Cash distributions					$ 186,000

EXCEL 34 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 35 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 36 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 38 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 122 141 1 false 27 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://stonyhillcorp.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://stonyhillcorp.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://stonyhillcorp.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://stonyhillcorp.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY (Unaudited) Sheet http://stonyhillcorp.com/role/CondensedConsolidatedStatementOfStockholdersEquity CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://stonyhillcorp.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION Sheet http://stonyhillcorp.com/role/NatureOfOperationsAndBasisOfPresentation NATURE OF OPERATIONS AND BASIS OF PRESENTATION Notes 7 false false R8.htm 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://stonyhillcorp.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - INVESTMENT Sheet http://stonyhillcorp.com/role/Investment INVESTMENT Notes 9 false false R10.htm 00000010 - Disclosure - CONVERTIBLE NOTE Sheet http://stonyhillcorp.com/role/ConvertibleNote CONVERTIBLE NOTE Notes 10 false false R11.htm 00000011 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://stonyhillcorp.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 11 false false R12.htm 00000012 - Disclosure - EQUITY Sheet http://stonyhillcorp.com/role/Equity EQUITY Notes 12 false false R13.htm 00000013 - Disclosure - SUBSEQUENT EVENTS Sheet http://stonyhillcorp.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 13 false false R14.htm 00000014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://stonyhillcorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 14 false false R15.htm 00000015 - Disclosure - INVESTMENTS (Tables) Sheet http://stonyhillcorp.com/role/InvestmentsTables INVESTMENTS (Tables) Tables http://stonyhillcorp.com/role/Investment 15 false false R16.htm 00000016 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details Narrative) Sheet http://stonyhillcorp.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details Narrative) Details http://stonyhillcorp.com/role/NatureOfOperationsAndBasisOfPresentation 16 false false R17.htm 00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://stonyhillcorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://stonyhillcorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies 17 false false R18.htm 00000018 - Disclosure - INVESTMENTS (Details) Sheet http://stonyhillcorp.com/role/InvestmentsDetails INVESTMENTS (Details) Details http://stonyhillcorp.com/role/InvestmentsTables 18 false false R19.htm 00000019 - Disclosure - INVESTMENTS (Details Narrative) Sheet http://stonyhillcorp.com/role/InvestmentsDetailsNarrative INVESTMENTS (Details Narrative) Details http://stonyhillcorp.com/role/InvestmentsTables 19 false false R20.htm 00000020 - Disclosure - CONVERTIBLE NOTE (Details Narrative) Sheet http://stonyhillcorp.com/role/ConvertibleNoteDetailsNarrative CONVERTIBLE NOTE (Details Narrative) Details http://stonyhillcorp.com/role/ConvertibleNote 20 false false R21.htm 00000021 - Disclosure - EQUITY (Details Narrative) Sheet http://stonyhillcorp.com/role/EquityDetailsNarrative EQUITY (Details Narrative) Details http://stonyhillcorp.com/role/Equity 21 false false R22.htm 00000022 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://stonyhillcorp.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://stonyhillcorp.com/role/SubsequentEvents 22 false false All Reports Book All Reports appb-20181231.xml appb-20181231.xsd appb-20181231_cal.xml appb-20181231_def.xml appb-20181231_lab.xml appb-20181231_pre.xml http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 40 0001477932-19-000451-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-19-000451-xbrl.zip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end

101.INS *		XBRL Instance Document

101.SCH *		XBRL Taxonomy Extension Schema Document

101.CAL *		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF *		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB *		XBRL Taxonomy Extension Label Linkbase Document

101.PRE *		XBRL Taxonomy Extension Presentation Linkbase Document

(1)	Incorporated by reference to the Registrant’s Registration Statement on Form S-1 (File No. 333-197443), filed with the Securities and Exchange Commission on July 16, 2014.

(2)	Incorporated by reference to the Registrant's Registration Statement on Form S-1/A (File No. 333-197443), filed with the Securities and Exchange Commission on October 16, 2014.

(3)	Incorporated by reference to the Registrant’s Current Report on Form 8-K (File No. 000-52223), filed with the Securities and Exchange Commission on November 10, 2016.

(4)	Incorporated by reference to the Registrant’s Current Report on Form 8-K (File No. 000-52223) filed with the Securities Exchange Commission on March 5, 2018

*	XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.